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Abstract 
 
Age-related macular degeneration (AMD) is a chronic, irreversible disease that robs 
individuals of vision, quality of life, and independence. It is the leading cause of 
blindness in industrialized countries. Sleep-disordered breathing (SDB) is a condition 
characterized by repeated episodes of apnea and/or hypopnea, insomnia, short sleep 
duration, and/or sleep disturbances (snoring, gasping, etc.). Because SDB has been shown 
to cause chronic hypoxia resulting in oxidative stress on the retina, it has been proposed 
that SDB may be associated with AMD. Based on the life course theory of chronic 
disease, this quantitative, cross-sectional study used data from the 2005–2008 National 
Health and Nutrition Examination Survey to study whether there was an association 
between SDB and AMD, including neovascular AMD and geographic atrophy in adults 
40 years and older. Descriptive statistics and logistic regression analyses were used. The 
results suggest that AMD is associated with diagnosed sleep disorders, including sleep 
apnea and insomnia, as well as sleep apnea symptoms of gasping snoring, snorting, and 
stopping breathing. The findings of this study highlight the importance of diagnostic 
screening and therapeutic intervention to treat SDB. Early diagnosis and therapy for SDB 
could address not only the comorbidities associated with SDB, but could also prevent or 
slow the progression of AMD. In turn, this would yield lower rates of vision loss, reduced 
comorbidities associated with vision loss, and reduced impact of AMD on the health care 
system and social and financial costs to society. 
Association Between Age-Related Macular Degeneration and Sleep-Disordered 
Breathing 
by 
Jeffrey A. Nau 
 
 
 
Master’s Medical Science, MCP Hahnemann University 2002 
BS Biology, Stony Brook University 1997 
 
 
 
 
 
Dissertation Submitted in Partial Fulfillment 
of the Requirements for the Degree of 
Doctor of Philosophy 
Public Health 
Walden University 
February 2017
 i 
 
Table of Contents 
List of Tables .......................................................................................................................v 
List of Figures .................................................................................................................... vi 
Chapter 1: Introduction to the Study ....................................................................................1 
Introduction ....................................................................................................................1 
Background ....................................................................................................................2 
Problem Statement .........................................................................................................6 
Purpose of the Study ......................................................................................................7 
Research Questions and Hypothesis ..............................................................................7 
Theoretical Framework ..................................................................................................9 
Nature of the Study ......................................................................................................12 
Definition of Terms......................................................................................................14 
Assumptions .................................................................................................................16 
Scope and Delimitations ..............................................................................................16 
Limitations ...................................................................................................................17 
Significance..................................................................................................................19 
Summary ......................................................................................................................21 
Chapter 2: Literature Review .............................................................................................23 
Introduction ..................................................................................................................23 
Literature Search Strategy............................................................................................25 
Theoretical Foundation ................................................................................................25 
AMD… ........................................................................................................................30 
 ii 
 
Risk Factors for AMD .......................................................................................... 33 
Classification and Severity Scale of AMD ........................................................... 37 
AMD Epidemiology.............................................................................................. 38 
SDB…. .........................................................................................................................40 
Classification and Severity Scale of SDB ............................................................. 43 
Risk Factors Associated with SBD ....................................................................... 44 
The Association of SDB and CVD ....................................................................... 46 
SDB and CVD....................................................................................................... 49 
SDB and CHD....................................................................................................... 50 
SDB Epidemiology ............................................................................................... 51 
AMD and SDB .............................................................................................................53 
SDB and Treatment for AMD ............................................................................... 59 
SDB Associations with AMD ............................................................................... 59 
Confounders .................................................................................................................61 
Summary ......................................................................................................................62 
Chapter 3: Research Method ..............................................................................................64 
Introduction ..................................................................................................................64 
Research Design and Rationale ...................................................................................64 
Research Hypotheses ...................................................................................................64 
Methodology ................................................................................................................66 
Population ............................................................................................................. 66 
Sampling and Sampling Procedures ..................................................................... 67 
 iii 
 
Procedures for Recruitment, Participation, and Data Collection .......................... 67 
Operationalization of Variables ............................................................................ 69 
Data Analysis Plan .......................................................................................................76 
Threats to Validity .......................................................................................................80 
Ethical Considerations .................................................................................................81 
Summary ......................................................................................................................82 
Chapter 4: Results ..............................................................................................................83 
Introduction ..................................................................................................................83 
Data Collection ............................................................................................................84 
Results ………………………………………………………………………………..85 
Descriptive Characteristics ................................................................................... 85 
Research Question 1: Chi-Square Analyses ......................................................... 93 
Research Question 2 and 3: Complex Samples Logistic Regression ................. 102 
Summary ....................................................................................................................103 
Chapter 5: Discussion ......................................................................................................105 
Introduction ................................................................................................................105 
Interpretation of Findings ..........................................................................................106 
Study Sample and Sociodemographic Characteristics ........................................ 106 
Association of SDB with AMD .......................................................................... 108 
Sociodemographic Characteristics ...................................................................... 113 
Association of SDB with Late AMD .................................................................. 114 
Overall Findings.................................................................................................. 115 
 iv 
 
Limitations of the Study.............................................................................................117 
Recommendations ......................................................................................................119 
Implications................................................................................................................121 
Conclusions ................................................................................................................122 
References ........................................................................................................................124 
Appendix A ......................................................................................................................164 
 
 
  
 v 
 
List of Tables 
Table 1. Apnea-Hypoapnea Index Severity Categories for OSA……………………...43 
Table 2. AMD Variables: NHANES 2005-2008………………………………………...70 
Table 3. SDB Variables: NHANES 2005-2008………………………………………….72 
Table 4. Demographic Variables: NHANES 2005-2008………………………………...75 
Table 5. Smoking Variables: NHANES 2005-2008……………………………………..75 
Table 6. Sociodemographic characteristics of NHANES Sample, Study Sample, and 
Weighted Study Sample………………………………………………………….90 
Table 7. Goodness of Fit Results from Comparison of NHANES and this Study’s Sample     
……………………………………………………………………………………92 
Table 8. SDB characteristics of NHANES Sample, Study Sample, and Weighted Study 
Sample……………………………………………………………………………93 
Table 9. Chi-square Test of Association of AMD and Sociodemographic     
Characteristics...………………………………………………………………….97 
Table 10. Chi-square Test of Association between AMD and SDB Characteristics.……99 
Table 11. Ordinal Logistic Regression Models: Association of SDB and AMD………102 
Table 12. Multivariate Model for Association of SDB and AMD……………………..104 
Table 13. Cox & Snell R2, Nagelkerke R2, and McFadden R2 Values, by Model….....105 
Table 14. Proportional Odds Testing: Separate Binomial Logistic Regression 
Model…………………………………………………………………………...106 
Table 15. Multivariate Model of the Association of Late AMD and Any Diagnosed Sleep   
Disorder……………………………………………………………………...................108 
 vi 
 
List of Figures 
Figure 1. Life Course Theory model of AMD pathogenesis incorporating the hypothesis 
of a potential association with SDB ...................................................................................11 
Figure 2. Life Course Causal Models ................................................................................27 
Figure 3. Life Course Cumulative Risk Model for AMD with SDB as a potential 
exposure. ............................................................................................................................28 
Figure 4. Participant Flowchart detailing the number of cases available for analysis. ......89 
Figure 5. AMD demographics (worse eye) in 5604 participants in the NHANES 2005–
2008 survey. .......................................................................................................................96 
 
1 
 
 
 
Chapter 1: Introduction to the Study 
Introduction 
The World Health Organization (WHO) ranks age-related macular degeneration 
(AMD) as the third leading cause of blindness globally behind cataracts and glaucoma 
and the leading cause of blindness in industrialized countries (World Health Organization 
[WHO], 2015). . By the year 2050, the estimate of people with AMD is expected to more 
than double from 2.07 million to 5.44 million (National Eye Institute, 2016a). Although 
the clinical understanding of AMD is continually evolving, the precise etiology of the 
disease remains elusive. A recently emerging area of interest is the impact of sleep and/or 
sleep-disordered breathing (SDB) on the development and treatment of AMD (Khurana 
et al., 2016). Currently, there exists a knowledge gap which this research was designed to 
address. 
SDB is a condition whereby episodes of cessation of breathing or apnea are 
repeated and/or an abnormally shallow rate of respiration (hypopnea) occurs (Peppard et 
al., 2013) . This disruption can be caused by complete or partial obstructions to the 
airway, known as obstructive sleep apnea, or by disorders such as chronic sinusitis, 
allergies, and obesity (Balachandran & Patel, 2014). It is estimated that 14% of males and 
5% of females in the United States meet the Medicare criteria for obstructive sleep apnea, 
which is an apnea/hypopnea score greater than 5, plus symptoms of daytime sleepiness 
(Peppard et al., 2013). Systematic monitoring of SDB is not currently performed in the 
United States  because it is costly and time-consuming (Peppard et al., 2013). Therefore, 
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the prevalence of SDB may be underestimated and undiagnosed subjects may be at risk 
for its serious long-term complications. 
Findings of this research could reinforce the need for diagnostic screening and 
therapeutic intervention to treat SDB. Early diagnosis and initiation of therapy for SDB 
would not only address the comorbidities associated with SDB, but may also prevent or 
slow the progression of AMD. Preventing or slowing the progression of AMD may result 
in lower rates of vision loss and reduced comorbidities associated with vision loss. In 
turn, this would help reduce the impact of AMD on the health care system and overall 
costs to society. 
In this chapter, I describe the following components of the study:  background; 
problem statement; purpose; research questions and hypotheses; nature of the study; 
conceptual framework; assumptions, scope and delimitations, limitations; and 
significance. 
Background 
AMD is a disease of the retina that causes photoreceptor degeneration (W. Wong 
et al., 2014). Currently, there are few effective preventive measures available to patients, 
for example, dietary supplements and smoking cessation, (Glaser et al., 2015). It was 
estimated in the year 2000 that AMD affected 1.75 million individuals in the United 
States (Friedman et al., 2004). This number has increased to 2.07 million in the decade 
since (NEI, 2016a). AMD exists in both dry and wet forms. The dry form is characterized 
by a slow degeneration of photoreceptors and the wet or neovascular AMD (nAMD) 
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form identified by the formation of new blood vessels in an area of the retina that is 
normally avascular (Leibowitz et al., 1980). Data from the 2005–2008 National Health 
and Nutrition Examination Survey (NHANES) estimated that the overall prevalence of 
AMD in the U.S. population was 6.5% (Klein et al., 2011). Joachim, Mitchell, Burlutsky, 
Kifley, and Wang (2015) provided estimates from the Blue Mountain Eye Study in 
Australia. They wrote that the 15-year incidence was 22.7% for early AMD and 6.8% for 
late (neovascular) AMD in subjects older than 49 years. Currently, the only therapy 
shown to have a preventive benefit for dry AMD is a combination of antioxidant 
supplements (Age-Related Eye Disease Study 2 Research Group, 2013). Treatment for 
the neovascular form of AMD was thought to have been revolutionized by the advent of 
anti-vascular endothelial growth factor (VEGF) therapy, although long-term outcomes 
have shown that the therapy is not sustainable and most patients do not achieve functional 
vision outcomes (Brown et al., 2006; Heier et al., 2012; Kaiser et al., 2007; Rasmussen et 
al., 2013; Schmidt-Erfurth et al., 2014).  
Research into risk factors associated with AMD has provided information on a 
number of variables that include age, smoking (Myers et al., 2014; Thornton et al., 2005; 
Velilla et al., 2013), race and/or ethnicity (Klein, Li, et al., 2013; W. Wong et al., 2014), 
family history (Seddon, Cote, Page, Aggen, & Neale, 2005), obesity (Clemons et al., 
2005), and a growing number of genetic mutations (Kanda et al., 2007; Klein, Myers, et 
al., 2013; Seddon et al., 2007; Triebwasser et al., 2015; van Lookeren Campagne, 
LeCouter, Yaspan, & Ye, 2014). Genetic studies have shown that inheritable mutations 
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may account for up to 70% of the risk for AMD and those that have been shown to be 
most strongly associated include the complement factor H (CFH) and the age-related 
maculopathy susceptibility 2/High Temperature Requirement A Serine Peptidase 1 
(ARMS2/HTRA1) genes (Kanda et al., 2007; Seddon et al., 2007) 
The landmark Wisconsin Sleep Cohort study estimated the prevalence of SDB in 
30–60-year-old subjects , who were currently employed at 9% in women and 24% in men 
(T. Young et al., 1993). The Wisconsin Sleep Cohort study has since been followed 
longitudinally to estimate the prevalence of SDB in the United States during the periods 
of 1988-1994 and 2007-2010 (Peppard et al., 2013). The prevalence of SDB in 2007-
2010 was 10% among 30-49 year old men; 17% among 50-70 year old men; 3% among 
30-49 year old women; and 9% among 50-70 year old women (Peppard et al., 2013). The 
authors estimated that prevalence since the period 1988-1994 has increased between 14% 
and 55%, depending upon the specific gender/age subgroup under study (Peppard et al., 
2013).  
SDB has been shown to cause disrupted sleep patterns, intermittent hypoxia, 
abnormal heart rhythms, hypertension, and increased intrathoracic pressure (Somers et 
al., 2008). Population based studies have illustrated an association between SDB and 
cardiovascular disease (Shahar et al., 2001); metabolic syndrome (Kawada, Otsuka, 
Nakamura, & Kon, 2015); hypertension (Geiger & Shankar, 2015); cognitive function 
(Addison-Brown et al., 2014; Blackwell et al., 2015); liver disease (Trzepizur et al., 
5 
 
 
 
2016); kidney disease (Molnar et al., 2015); quality of life; genetic mutations, specifically 
apolipoprotein epsilon 4 (Gottlieb et al., 2004); and mortality (Gami et al., 2013). 
There is a gap in the knowledge about the association between AMD and SDB.  
Currently, Retina Specialists and Ear Nose and Throat (ENT) Specialists do not routinely 
co-manage patients. Recently, there has been an increased interest in understanding the 
association between these two chronic diseases. A statistically significant association 
(OR=3.3; 95% CI 1.32-8.27) between short sleep duration and neovascular AMD (Perez-
Canales, Rico-Sergado, & Perez-Santonja, 2016). Similar findings have been shown with 
OSA and AMD (Keenan, Goldacre, & Goldacre, 2016). Sleep duration may also be 
associated with geographic atrophy (Khurana et al., 2016). 
The current study has potential implications for positive social change. The 
resulting data may provide health care providers and patients a better understanding of 
how to better manage both AMD and SDB from a multi-disciplinary approach and could 
support the creation of public health interventions to improve screening, prevention 
and/or treatment of SDB, ultimately resulting in better AMD outcomes. Patients and 
physicians do not currently see vision loss as a consequence of SDB. But fear of vision 
loss could increase patients’ impetus for getting screened for SDB, improving compliance 
with therapies, such as continuous positive airway pressure (CPAP), and adding to the 
cost-effectiveness argument with payers for covering screening and prevention. A more 
detailed discussion of the data on AMD and SDB is provided in Chapter 2.  
6 
 
 
 
Problem Statement 
 Age-related eye disease is a growing public health problem throughout the world 
(Pascolini & Mariotti, 2012)   The human retina requires a significant amount of energy 
to keep its photoreceptors at an optimum functioning state and when oxygen is removed a 
significant increase in lactate ensues (Ames, Li, Heher, & Kimble, 1992). Based on this 
high-energy demand, nature has given it the greatest blood flow of any organ in the body 
relative to its size (Blasiak, Petrovski, Vereb, Facsko, & Kaarniranta, 2014; Boltz et al., 
2010; Remsch, Spraul, Lang, & Lang, 2000). This places the retina in a precarious state 
when oxygen levels in the blood drop. Chronic apnea/hypopnea episodes during SDB can 
lead to damage from ischemia and hypoxia. In some cases, chronic apnea/hypopnea 
episodes may lead to pathological changes and/or irreversible damage to the retina 
(Blasiak et al., 2014). 
SDB is shown to be commonly underdiagnosed or misdiagnosed, and 
subsequently untreated (Gibson, 2004; T. Young, Evans, Finn, & Palta, 1997). SDB can 
be treated effectively with CPAP, although many patients are poorly compliant with the 
therapy (Weaver & Grunstein, 2008). Based on the combination of underdiagnosis,- 
misdiagnosis, and poor compliance, a significant portion of patients experience regular 
apneas and hypopneas during sleep (Peppard et al., 2013). Researching the possible 
association between AMD and SDB addresses a current gap in the literature; research 
could lead to additional understanding and thus promote awareness, screening, and 
improved adherence to preventive therapy. 
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Purpose of the Study 
The purpose of this quantitative, cross-sectional study was to evaluate the 
association between SDB and AMD in noninstitutionalized U.S. adults using the 2005–
2008 NHANES dataset. Based on nationally representative data, I investigated whether 
respondents with SDB (independent variable) had an increased prevalence of AMD 
(dependent variable). The intent of the study was to address the gap in understanding 
whether SDB is associated with the development of AMD and to add to the current 
literature on the association between the two diseases. using data from the 2005–2008 
NHANES retinal fundus photograph evaluation and sleep disorder questionnaire (CDC, 
2016a). I selected this dataset due to the availability of AMD data based on masked 
central grading of retinal fundus photographs unique to this NHANES sampling period. 
Research Questions and Hypothesis 
The research questions and associated hypotheses that will guide this study are as 
follows:  
Research Question 1: Is there an association between self-reported SDB and 
fundus photography identified AMD among adults 40 years and older who 
participated in the 2005–2008 NHANES survey before and after 
controlling for age, smoking, and BMI? 
H01: There is no association between self-reported SDB and fundus 
photography identified AMD among adults 40 years and older who 
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participated in the 2005–2008 NHANES survey before and after 
controlling for age, smoking, and BMI. 
H11: There is an association between self-reported SDB and fundus 
photography identified AMD among adult 40 years and older who 
participated in the 2005–2008 NHANES survey before and after 
controlling for age, smoking, and BMI. 
Research Question 2: Is there an association between self-reported SDB and 
fundus photography identified neovascular AMD among adults 40 years 
and older who participated in the 2005–2008 NHANES survey before and 
after controlling for age, smoking, and BMI? 
H02: There is no association between self-reported SDB and fundus 
photography identified neovascular AMD among adults 40 years and 
older who participated in the 2005–2008 NHANES survey before and 
after controlling for age, smoking, and BMI. 
H12: There is an association between self-reported SDB and fundus 
photography identified neovascular AMD among adult 40 years and 
older who participated in the 2005–2008NHANES survey before and 
after controlling for age, smoking, and BMI. 
Research Question 3: Is there an association between self-reported SDB and 
fundus photography identified geographic atrophy among adults 40 years 
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and older who participated in the 2005–2008 NHANES survey before and 
after controlling for age, smoking, and BMI? 
H03: There is no association between self-reported SDB and fundus 
photography identified geographic atrophy among adults 40 years and 
older who participated in the 2005–2008 NHANES survey. 
H13: There is an association between self-reported SDB and fundus 
photography identified geographic atrophy among adult 40 years and 
older who participated in the 2005–2008 NHANES survey. 
Theoretical Framework 
Life course theory, or the life course approach, is based on an interdisciplinary 
framework for guiding research on health, human development, and aging (D. Kuh, Ben-
Shlomo, Lynch, Hallqvist, & Power, 2003). The approach is applicable to chronic 
disease, infectious disease, and a number of other areas of public health (Ben-Shlomo & 
Kuh, 2002; D. Kuh et al., 2003; Lynch & Smith, 2005). The theory can help explain how 
biological, behavioral, environmental, and psychosocial processes that operate across an 
individual’s life course, or across generations, may influence the development of disease 
risk (D. Kuh et al., 2003). The time factor for the development of AMD is important 
within the context of this framework. AMD has a predictably long latency period and 
exposures—for example, recurrent hypoxic episodes during SDB which are likely to 
occur earlier in life—may promote late disease progression (Lynch & Smith, 2005). 
Although the study collected data on SDB from a single point in time due to the cross-
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sectional design, it is likely that the SDB data represent an ongoing condition. Evidence 
from the literature on the development of AMD implicated a number of risk factors: age, 
smoking (Myers et al., 2014; Thornton et al., 2005; Velilla et al., 2013), race and/or 
ethnicity (Klein, Li, et al., 2013; W. Wong et al., 2014), family history (Seddon, Cote, et 
al., 2005), obesity (Clemons et al., 2005), and a number of genetic mutations (Kanda et 
al., 2007; Klein, Myers, et al., 2013; Seddon et al., 2007; Triebwasser et al., 2015; van 
Lookeren Campagne et al., 2014). As previously stated, genetic studies have shown that 
inheritable mutations may account for up to 70% of the risk for AMD (Seddon, Cote, et 
al., 2005; van Lookeren Campagne et al., 2014). The mutations, present from birth, may 
represent the first “hit” that occurs with the life-course progression of AMD. Although 
the genetic associations are strong for AMD, the penetrance of the disease varies with 
some individuals who present with mild signs of disease, such as drusen, a yellowish 
deposit under the retina, alone, others with the non-neovascular form of AMD, and 
finally 10% of patients progressing to severe AMD, including choroidal 
neovascularization and geographic atrophy (Friedman et al., 2004; Klein et al., 2011). 
This evidence suggests that additional factor(s) can influence AMD patients in addition to 
their genetic predisposition and thus cause their disease to progress later in life. These 
represent additional hits that may increase the risk of developing AMD. Figure 1 
illustrates a life course theory model applied to the study of AMD pathogenesis and 
incorporating the hypothesis of a potential association with SDB. 
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Figure 1. Life course theory model of AMD pathogenesis incorporating the hypothesis of 
a potential association with SDB. 
 
A number of the criteria for causation proposed by Bradford Hill (1965) are 
relevant to AMD and SDB. As discussed, there is biological plausibility that ischemia 
and hypoxia play a role in AMD (Blasiak et al., 2014; Grunwald, Metelitsina, Dupont, 
Ying, & Maguire, 2005). Coherence exists in that the cause-and-effect association of 
ischemia and hypoxia with the disease fit the natural history of the disease (Grunwald et 
al., 2005). There is a temporal relationship between the peak presentation of SDB and the 
presentation of signs associated with early AMD (Bixler, Vgontzas, Ten Have, Tyson, & 
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Kales, 1998; Bourne et al., 2014). This study and its inherent research questions 
attempted to add to the data related to causality by providing evidence of consistency, 
strength of association, and biological gradient. A more detailed discussion of the life 
course theory of chronic disease is presented in Chapter 2. 
One other conceptual model, the chronic care model (CCM), was assessed for this 
study (Wagner et al., 2001). The CCM was initially developed by Wagner et al. in 1996 
and its’ aim was to “transform the daily care for patients with chronic illnesses from 
acute and reactive to proactive, planned, and population-based” (Wagner, Austin, & Von 
Korff, 1996, p. 13). The CCM addresses the shortcomings of the current delivery of care 
to chronic diseases, as they are often managed much the same way as an acute condition. 
This model does not integrate well with the research question of this study as it does not 
take into account the events over the course of the patients’ lifetime that may have 
contributed to disease. For this reason, the life course theory was chosen as the theoretical 
framework for this study. 
Nature of the Study 
In this study, I used a quantitative, cross-sectional approach to understand 
whether SDB characteristics are associated with early or late AMD. Quantitative data are 
most appropriate to investigate this association with appropriate inferential testing. Data 
from the 2005–2008 NHANES retinal fundus photograph evaluation, and sleep disorder 
questionnaire were used in this analysis (CDC, 2016a).  Because the NHANES survey is 
a national survey that includes a representative sampling of the U.S. population, with 
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oversampling of certain underrepresented groups (including the elderly as it pertains to 
this study), the data will enable extrapolation to the U.S. population (CDC, 2011). The 
surveys from the years 2005-2006 and 2007-2008 contain data from a retinal fundus 
photograph evaluation (choroidal neovascularization, geographic atrophy, AMD 
severity), and sleep disorder questionnaire (SDB severity based on questions about sleep 
apnea, insomnia, short sleep duration, and other sleep disturbances). Retinal fundus 
photography from these sampling frames was graded by masked graders at the Wisconsin 
Epidemiological Grading Center (CDC, 2005). This combination of survey and 
examination methodology was appropriate for answering this research question because it 
allowed me to use data from the U.S. population that included individuals who may have 
AMD but are unaware and/or undiagnosed. Grading of fundus photographs by a central 
reading center reduces misclassification bias by categorizing participants based on 
photography findings and not relying upon participant recall. Participants who were not 
aware, or had not been formally diagnosed with AMD, were identified by trained 
independent graders (CDC, 2005).  
To answer the research questions, I conducted a chi-square test for association to 
determine any differences in the distribution of AMD across sociodemographic, lifestyle, 
and sleep characteristics. Cumulative odds ordinal logistic regression (OLR) with 
proportional odds (ordinal dependent variable with responses no AMD, early AMD, late 
AMD) regression and binomial logistic regression modeling (dependent variable with 
responses no choroidal neovascularization, choroidal neovascularization present; no 
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geographic atrophy, geographic atrophy present) were fit to understand the association 
between AMD and sleep parameters after adjustment for sociodemographic and lifestyle 
factors. Survey specific sampling design variables and sampling weights were 
incorporated in the analyses to account for the complex multistage sampling design of 
NHANES. Definitions for early and late AMD with the 2005–2008 dataset have been 
previously defined (Klein et al., 1991) and operationalized from this same dataset looking 
at AMD prevalence (Klein et al., 2011). OLR allowed me to use the robust data provided 
from the masked reading of fundus images. Logistic regression was performed to 
determine whether the presence of AMD could be predicted by self-reported SDB, 
categorized by the definitions of Chen, Redline, Shields, Williams, & Williams (2014). 
Additional covariates were included in the model: age, race/ethnicity, smoking history, 
body mass index (BMI), and diabetes status. ORs with 95% confidence intervals are 
reported. 
Definition of Terms 
AMD): A degenerative disease of the retina that primarily impacts the macular 
region and is currently the leading cause of blindness in industrialized countries (NEI, 
2016b; WHO, 2015) 
Choroidal neovascularization: Often termed neovascular AMD (nAMD) or wet 
AMD, choroidal neovascularization is the formation of new and/or abnormal blood 
vessels from the choroid layer of the retina. In choroidal neovascularization, the vessels 
grow underneath the macula region of the retina, which under normal conditions is 
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avascular. These vessels, due to their immaturity, leak fluid, lipid, and proteins into the 
surrounding tissues. Ultimately, this process results in scar formation in the central 
portion of the retina that negatively impacts vision (NEI, 2016b). 
Continuous Positive Airway Pressure: A mechanical ventilation device that is 
placed over the nose and/or mouth during sleep to provide positive airway pressure that 
opens the area of obstruction and allows for improved oxygen saturation. Although 
highly effective, most subjects are non-compliant with the treatment modality (Weaver & 
Grunstein, 2008). 
Drusen: Drusen are yellowish deposits under the retina that are present and can be 
seen in early AMD. Components of drusen include lipid, inflammatory proteins, and 
photoreceptor breakdown products (Mullins, Russell, Anderson, & Hageman, 2000).  
Geographic Atrophy: Defined as the late stage of dry AMD. Geographic atrophy 
consists of areas of retina devoid of the retinal pigment epithelial layer with subsequent 
loss of the overlying photoreceptor layer (NEI, 2016). 
OSA: A condition that occurs during sleep where a subjects tongue falls back 
against his or her soft palate, causing the soft palate and uvula fall back against the back 
of the throat, mechanically closing the airway (American Sleep Apnea Association, 
2016). 
Polysomnography :  Also commonly called a sleep study, is a clinical procedure 
that records brain activity, the oxygen level of the blood, heart rate and breathing, and 
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documents eye and leg movements during the overnight study (Weaver & Grunstein, 
2008) 
SDB:  Refers to a number of conditions that impact the overall quality of sleep for 
an individual that include but are not limited to a formal diagnosis of sleep apnea. In the 
context of the 2005–2008 NHANES data, this includes patient reported sleep apnea; 
sleep apnea symptoms such as habitual snoring, snorting, or stopping breathing; 
insomnia; short sleep duration; and any sleep disorder diagnosed by a physician or other 
health professional (Chen et al., 2014). 
Assumptions 
The 2005–2008 NHANES dataset was used for this study. I assumed that the 
sample I analyzed was representative of noninstitutionalized adults over 40 years in the 
United States. In addition, I assumed that the NHANES Digital Grading Protocol for 
evaluating  fundus photographs was followed (CDC, 2005). Similar grading and staging 
systems for AMD have been shown to have high reliability compared to standard clinical 
examination (Bird et al., 1995; Seddon, Sharma, & Adelman, 2006). Masked grading of 
the retina fundus images was important to this study in order to provide reliable 
categorization of AMD status. 
Scope and Delimitations 
The 2005–2008 NHANES dataset was chosen for this study because it 
represented a unique cross-sectional dataset with masked grading of fundus photography 
for retinal disease. While SDB was based on participants’ self-report of disease, masked 
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grading of AMD severity removed this need and minimized recall and/or report bias. In 
addition, the severity grading of AMD allowed for additional information about the 
disease to be incorporated into the analyses.  A simple dichotomous answer from patient 
self-report as to whether disease is present or absent would limit the amount of 
information available for analyses and potentially introduce additional recall bias. 
The NHANES dataset is a purposive sample from which an approximation of the 
U.S. population was developed. This study was delimited to the population of the United 
States in which the NHANES dataset was collected. Thus, the results are valid and 
generalizable to the U.S. population where the survey was conducted. The results may 
not be generalized to other non-U.S. populations. NHANES used oversampling to 
improve the precision of estimates of health status indicators for population subgroups of 
particular public health interest (Johnson et al., 2013). In 2005–2006, people aged 70 and 
over were oversampled, while in 2007–2008 people aged 80 and over were oversampled 
(Johnson et al., 2013). As AMD prevalence increased significantly with increasing age, 
additional sampling of any subjects over the age of 40 will improve the precision of 
estimating AMD prevalence in those subgroups (W. Wong et al., 2014). 
Limitations 
This study was subject to several limitations. First, given my use of cross-
sectional data I could not make a causal inference as to whether SDB leads to the 
development of late or early AMD. Based on the limitations of the study design, this 
study could only elucidate a better understanding of the association between these two 
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conditions. It is possible that my findings could be explained by an underlying 
mechanism that affects both AMD and SDB—there are a number of shared confounders 
that include age, gender, obesity, diabetes status, and past and current smoking status (see 
Chapter 2). Future research should be aimed at understanding and elucidating whether 
SDB can cause AMD. 
Second, SDB variables were assessed by self-reported questionnaire and thus 
were subject to measurement and/or report bias. At the same time, however, multiple 
questions surrounding SDB could also be a strength in that the variables collected in the 
NHANES sleep questionnaire represented a wide range of questions on the topic of SDB. 
Important information collected using the questionnaire might be lost if there were only 
information on the absence/presence of SDB as diagnosed by polysomnography.  
Third, there are inherent limitations to the NHANES sampling methodology 
(CDC, 2011). The main limitation is that the survey incorporates only 
noninstitutionalized U.S. citizens. As AMD presents primarily in the elderly population, a 
significant number of potential participants could have been in nursing homes, hospitals, 
and long-term care facilities (Klein et al., 2011). In addition, a small number of 
participants opted out of, or were excluded from, undergoing digital fundus photography. 
Also excluded were participants having no light perception, severe visual impairment in 
both eyes, or an infection in at least one eye (CDC, 2005). Finally, the NHANES survey 
data might not contain a representative sample of certain underrepresented age and/or 
ethnic groups (Johnson et al., 2013). 
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Fourth, a number of biases are inherent in survey research (Choi & Pak, 2005). 
Nonresponse bias is a possibility in surveys such as NHANES as answers of participants 
may differ from the potential answers of those participants who did not answer. There is 
variability in the number of participants completing each specific questionnaire 
(demographics, diabetes, sleep, etc.). Survey research such as the NHANES is subject to 
recall bias from self-reported health outcomes that can ultimately result in subsequent 
misclassification bias (Szklo & Nieto, 2014). The NHANES survey has been compared to 
other surveys (Behavioral Risk Factor Surveillance System, National Health Interview 
Survey, and National Survey on Drug Use) using self-reported public health data and is 
found to have comparable predictive validity with these instruments (Li et al., 2012; 
Pierannunzi, Hu, & Balluz, 2013). Additionally, the dependent variable in these analyses 
was obtained from centralized masked grading of fundus photographs, which eliminates 
this bias. 
Significance 
In this study, I examined whether insufficient sleep or sleep disturbances (SDB) 
are associated with AMD using a sample of the U.S. population. U.S. Census Bureau 
projections have estimated that the number of Americans over 65 years of age will more 
than double to 87 million by the middle of this century (United States Census Bureau, 
2015b). Thus, the number of persons with AMD is estimated to double by 2050, from 
2.07 to 5.44 million patients (NEI, 2015). The public health impact of AMD is 
significant, not only due to the increase in population blindness, but to the  number of 
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physical and mental comorbidities associated with visual impairment (Court, McLean, 
Guthrie, Mercer, & Smith, 2014).  
The results from this study are expected to add to the current body of literature on 
the association between SDB and AMD. This additional understanding may have 
important public health implications for promoting improved screening and treatment of 
SDB in order to reduce the impact of AMD on the health of those older than 40 years. In 
addition, an improved preventative treatment for AMD would decrease its costs in the 
healthcare system. CPAP therapy has been shown to be effective in reducing morbidity 
and mortality, although patients are highly noncompliant (Weaver & Grunstein, 2008). In 
a poll conducted by Research!America and the Alliance for Eye and Vision Research 
(AEVR), the fear of blindness was one of the top four "worst things that could happen to 
you" for all respondents, including cancer, Alzheimer’s disease, and Human 
Immunodeficiency Virus/Acquired Immune Deficiency Syndrome () (Association for 
Research and Vision in Ophthalmology, 2014). The fear of blindness can be harnessed 
during discussions between providers and patients; the fear of losing vision may promote 
compliance with CPAP therapy. Conversely, for those patients who present with signs of 
AMD, the retina specialist may provide referral to a sleep clinic for SDB diagnosis. Early 
diagnosis and initiation of therapy for SDB could address not only the comorbidities 
associated with SDB, but they could also prevent or slow the progression of AMD. This, 
in turn, would lower the rates of vision loss, reduce comorbidities associated with vision 
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loss, and reduce the impact of AMD on the health care system and on the overall cost to 
society. 
Summary 
AMD represents a serious global public health problem. With an aging population 
and increasing life expectancy, AMD is expected to have a greater public health impact 
in the future. Although in recent years, data has emerged that elucidate a strong genetic 
association with AMD, the incomplete penetrance of the disease suggests that underlying 
mechanisms are still poorly understood. SDB represents a potentially important variable 
in the pathway of AMD pathogenesis (Figure 1).  
In this chapter, I discussed the epidemiology of AMD and SDB, presented a brief 
overview of the extant literature on these conditions and their potential relationship.  I 
presented the problems associated with an aging population and the consequences of 
AMD and suggested this research is needed to further explore SDB as a risk factor for 
this condition. I specified the research questions related to this research and the 
quantitative methodology I used to address them. I also justified the use of the life course 
theory as a framework for this research. An overview of the assumptions, scope and 
limitations, including those based on the use of secondary data, of the study was 
provided. Lastly, I concluded with a discussion on the significance of the current study 
and implications for positive social change.  
A detailed review of the literature on AMD and SDB is presented in Chapter 2. In 
Chapter 3 I describe the research methodology, including the dependent, independent, 
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and confounding variables, and the statistical testing was used to answer the research 
questions. The results of this study are reported in Chapter 4; the summary, discussion, 
and conclusions are presented in Chapter 5.
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Chapter 2: Literature Review 
Introduction 
The purpose of this quantitative, cross-sectional study was to evaluate the 
association between SDB and AMD in noninstitutionalized U.S. adults based on 
NHANES 2005-2008. Findings from this study will add to the current understanding of 
the associations between these two chronic diseases. 
The association between AMD and SDB is not well understood. (Keenan et al., 
2016; Perez-Canales et al., 2016) suggest that there is an association; Khurana et al. 
(2016) does not.  Khurana et al. (2016) have also shown an association  between SDB 
and late AMD (geographic atrophy) alone.  
AMD is the third leading cause of blindness globally behind cataracts and 
glaucoma; it is the leading cause of blindness in developed countries (WHO, 2015).  
Because AMD is a disease that presents later in life, the elderly population is 
disproportionately affected (WHO, 2015). The United Nations (UN) (2015) estimates that 
globally, the population over 60 years of age is the fastest growing and is expected to 
increase by 45% by the middle of the century. Thus, in the  United States, the U.S. 
Census Bureau projects that 1 in 5 Americans will be over the age of 65 by 2050 (United 
States Census Bureau, 2015b). Given that AMD is age related, it is likely that as the 
population grows older AMD will become a major public health problem. Wong et al. 
(2014) performed a systematic review and meta-analysis of all population-based studies 
[on what exactly?] that used retinal photographs and standardized grading classifications 
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to determine the presence of disease. By their estimation, AMD is prevalent in 
approximately 9% of the global population, which suggests that 196 million people will 
have AMD by the year 2020 (W. Wong et al., 2014). The cause(s) of AMD remain 
elusive. Data suggest a strong genetic association as well as a number of risk factors ,  
including age, smoking (Myers et al., 2014; Thornton et al., 2005; Velilla et al., 2013), 
race and/or ethnicity (Klein, Li, et al., 2013; W. Wong et al., 2014), family history 
(Seddon, Cote, et al., 2005), obesity (Clemons et al., 2005), and a number of genetic 
mutations (Kanda et al., 2007; Klein, Myers, et al., 2013; Seddon et al., 2007; 
Triebwasser et al., 2015; van Lookeren Campagne et al., 2014). Despite a significant 
amount of data supporting risk factors, the cause of AMD remains elusive. SDB causality 
on the other hand is characterized with a higher degree of certainty. 
SDB is defined as a number conditions, including central sleep apnea (CSA), 
OSA, and sleep-related hypoventilation or hypoxemic syndromes (American Academy of 
Sleep Medicine, 2014). During breathing-impaired sleep, the retina does not receive 
appropriate oxygenation and nutrition, and thus is at risk for chronic and irreversible 
damage. There is mounting evidence that SDB may be associated with AMD 
pathogenesis and with retinal disorders in general (Barak, Sherman, & Schaal, 2012; 
Boland et al., 2004; Boltz et al., 2010; Huseyinoglu et al., 2014; Perez-Canales et al., 
2016)This literature review covers the epidemiology of AMD and SDB, the risk factors 
for each disease, the impact of SDB on the treatment of AMD, and finally the association 
between AMD and SDB. There is also a review of the literature on the association 
25 
 
 
 
between the two diseases and their relationship to the systemic and retinal vascular 
system.  
Literature Search Strategy 
PubMed and Google Scholar were used to identify cohort or cross-sectional 
studies that investigated the possibility of an association between AMD and SDB The 
following Medical Subject Heading (MeSH) terms were used: age-related macular 
degeneration, macular degeneration, choroidal neovascularization, GA, SBD, OSA, and 
sleep apnea. The searches yielded more than 15,000 articles on these two chronic 
diseases. To whittle down this number, the peer-reviewed articles were selected only if 
(a) they were published after 1993, in English and in full text, and only if (b) the subjects 
were over the age of 18 or they used the measure of Apnea-Hypopnea Index (AHI), 
Respiratory Disturbance Index (RDI), self-reported physician diagnoses, or self-reported 
sleep duration were included in the review.  This narrowed down the total to about 300 
articles. 
 
.  
Theoretical Foundation 
The WHO has adopted the life course approach as one of its overarching 
principles in the Global Action Plan for the Prevention and Control of Noncommunicable 
Diseases (WHO, 2013). The life course theoretical model is based on an interdisciplinary 
framework for guiding research on health, human development and aging (Diana Kuh & 
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Ben-Shlomo, 2004). The origin of this theory can be traced back to research investigating 
the impact of the Great Depression of the 1930s on individual and family pathways 
(Elder, 1974). Elder (1974) used data from longitudinal studies to investigate the impact 
of this time period on the long-term development of children born in the 1920s. As Kuh 
et al. (2004) stated, the life course approach to epidemiology is more than the mere 
collection of longitudinal data for analysis or associated with a particular research 
methodology. Important components of the theoretical model are the temporal 
relationships of the exposures and the relationships between these exposures. A challenge 
that is often faced by practitioners of life-course epidemiology is how to translate the 
findings into public health interventions as the biological, social and/or environmental 
exposures have happened in the past. There are three main life-course models: the 
cumulative exposure model, the chains of risk model, and the critical period model 
(Diana Kuh & Ben-Shlomo, 2004). The models are not necessarily discreet and it is 
possible that they may exist simultaneously or as slight variations with aspects of 
multiple models (D. Kuh et al., 2003). The critical period model (Figure 2a) is based on 
the premise that exposure(s) acting during a specific period (in utero for example) can 
impart lifelong effects on the structure and/or function of organs and tissues in the body 
(Nishi et al., 2015). These exposures can exert effects independently or in concert with 
other exposures (Figure 2a). The chains of risk model (Figure 2b) posits that a sequence 
of linked exposures act in a way such that a harmful exposure results in an exposure to a 
subsequent harmful event, thus increasing risk (Nishi et al., 2015). The cumulative risk 
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model is based on the accumulation of a number of types of risks that lead to long-term 
damage and disease development (Nishi et al., 2015). This model differs from the chains 
of risk model in that the exposures can work independently from one another. The 
cumulative risk model (Figure 2c) was proposed as the most appropriate to explain the 
relationship with SDB and AMD. 
 
 
Figure 2. Life course causal models. Adapted with permission (Appendix A) from A Life 
Course Approach to Chronic Disease Epidemiology (Page 10), by D. Kuh, 2004, New 
York: Oxford University Press. Copyright 2004 by the Oxford University Press.   
 
A cumulative risk model of AMD is illustrated in Figure 3.  
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Figure 3. Life Course Cumulative Risk Model for AMD with SDB as a potential 
exposure. 
 
Time is an integral component of life course theory and is an undercurrent 
exposure in the cumulative risk model of AMD. Age-related changes in the eye are not 
specifically called out as a discrete exposure, but should be considered an exposure that 
continually exists in the background of the model. Numerous studies have shown that 
increasing age is associated with increasing risk of disease (Tomany et al., 2004). There 
are several temporally associated exposures that have been shown to highly related to the 
development of AMD. AMD has been associated with a number of genetic mutations, 
most specifically with the genes that code for CFH and the ARMS2/HTRA1 gene (Kanda 
et al., 2007; Seddon et al., 2007). The CFH gene has been shown to regulate the 
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Complement system and keep Complement mediated inflammation under control (Zipfel, 
Lauer, & Skerka, 2010). Mutation of the gene removes the protective effect and increases 
inflammatory response in the retina. Both CFH and ARMS2/HTRA1 mutations have 
been shown to be associated with drusen formation and progression of AMD (Dietzel et 
al., 2014). These early exposures present at births represent the first in a series of 
potential exposures as shown in Figure 3.  
Although the reduction in smoking is one of the most successful Public Health 
victories in the United States, exposure in early adult life and continued smoking for the 
current >40 age group is still significant (Holford, Levy, & Meza, 2016). It has been 
shown that compared to nonsmokers, past and current smokers develop late stage AMD a 
mean of 4.9 and 7.7 years sooner, respectively (p < 0.001 for both) (Lechanteur et al., 
2015). When risk alleles for CFH and ARMS2/HTRA1 mutations and smoking are taken 
into account, late stage AMD develops 12.2 years sooner, on average, then those with no 
risk alleles (p < 0.001) (Lechanteur et al., 2015).   
SDB represents a third, and potentially important exposure that may add to the 
cumulative risk of developing AMD with hypoxia placing additional oxidative stress on 
the already exposed retina (Barak et al., 2012; Keenan et al., 2016; Khurana et al., 2016; 
Perez-Canales et al., 2016). Blasiak et al. (2014) have implicated hypoxia and oxidative 
stress as important factors in the pathogenesis of AMD. Although the authors did not 
speculate on the specific causes of hypoxia, their opinion was that anything that can 
impair the blood supply to the retina might lead to hypoxia, oxidative stress, and cellular 
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dysfunction. Chronic hypoxic episodes due to SDB could be a potential initiator of this 
cascade. 
AMD 
AMD is a degenerative retinal disease primarily affecting the photoreceptor and 
retinal pigment epithelium tissue layers leading to a progressive loss of vision. Early 
AMD presents as lipid rich deposits called drusen and/or mild pigmentary changes in the 
retina, normally without corresponding vision loss (Lim, Mitchell, Seddon, Holz, & 
Wong, 2012). Vision loss from AMD usually is caused by one of two progressive 
degenerative processes termed choroidal neovascularization (wet AMD); neovascular 
AMD (nAMD) or geographic atrophy (dry AMD). Choroidal neovascularization 
constitutes abnormal blood vessel formation in the sub-retinal pigment epithelial and 
subretinal spaces (Lim et al., 2012). This form of AMD can cause dramatic reductions in 
visual acuity due to exudation, pigment epithelial layer detachment (PED), retina pigment 
epithelium tears, and ultimately leads to scarring of the retina (van Lookeren Campagne 
et al., 2014; Yonekawa, Miller, & Kim, 2015). Geographical atrophy is characterized by 
loss of the choriocapillaris layer of the retina and subsequent atrophy of the overlying 
retinal pigment epithelial layer (Lim et al., 2012). This loss of critical tissue layers that 
keep rods and cones healthy and functioning causes photoreceptor loss and subsequent 
decline in visual acuity. Although this process is generally results in more gradual visual 
acuity loss as compared to an acute decline with choroidal neovascularization, both 
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processes can be equally detrimental to quality of life and independence for patients 
(Coleman et al., 2010). 
Patients with nAMD usually present to general ophthalmologists in their late 60s 
or 70s, with a complaint of varying degrees of vision loss and/or metamorphopsia (Klein 
et al., 2011; Ryan, 2013). The defining feature of nAMD is the presence choroidal 
neovascularization, primarily diagnosed based on fluorescein angiography (Lim et al., 
2012). Choroidal neovascularization is the presence of a new blood vessel that originates 
in the choroidal circulation of the retina and can be found underlying or penetrating 
Bruchs membrane, violating the structural integrity of the blood retina barrier. This new 
vessel emerges within the normally avascular macula region and due to its immature 
morphology leaks serous and/or blood exudates into the surrounding retina tissue (Ryan, 
2013; van Lookeren Campagne et al., 2014; Yonekawa et al., 2015). The end product of 
this disease process is fibrous scarring of the retina and irreversible vision loss (Lim et 
al., 2012). Subjects can be affected unilaterally or bilaterally (NEI, 2016b). Having 
choroidal neovascularization in one eye predicts a higher risk for development of 
choroidal neovascularization in the fellow eye (Silva et al., 2011). Current therapy for 
nAMD consists of regular intraocular injections of anti-VEGF medications (Lim et al., 
2012). At the present time there are no preventive therapies available for nAMD. 
Dry AMD is progressive disease with less acute symptom onset when compared 
to nAMD and is a significant cause of moderate and severe loss of central vision in the 
elderly population (Lim et al., 2012; Ryan, 2013). The disease is diagnosed based on a 
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dilated fundus examination and diagnostic imaging including fundus photography, fundus 
autofluorescence, and optical coherence tomography (OCT). Dry AMD is characterized 
by the presence of drusen (yellowish deposits that develop within the macula) located 
under the retinal pigment epithelial layer that can be visualized during examination and 
documented based on fundus photography and OCT (Ryan, 2013). In dry AMD, thinning 
of the retinal pigment epithelial layer in the macula develops, along with other age-
related changes to the adjacent retinal tissue layers. When severe, the late stage of dry 
AMD is associated with thinning and loss of function of the neural retinal located above 
the affected retinal pigment epithelial layer (Ryan, 2013). This collective phenotype in 
late stage dry AMD is termed geographic atrophy. The progressive degeneration of light-
sensitive photoreceptor cells in geographic atrophy leads to severe visual loss in affected 
eyes. In addition, dry AMD can progress to the nAMD form of the disease (Holz, Strauss, 
Schmitz-Valckenberg, & van Lookeren Campagne, 2014). Dry AMD is the most 
common form of the disease, occurring in 85%-90% of AMD cases (Klein, Peto, Bird, & 
Vannewkirk, 2004). Currently, no approved therapy exists for non-neovascular AMD. 
The Age-Related Eye Disease Study (AREDS) has shown that taking lutein and 
zeaxanthine supplements (and eating those foods rich in these nutrients such as spinach 
and collard greens) is associated with a decreased risk of AMD and late stage AMD, 
which includes choroidal neovascularization and geographic atrophy (Age-Related Eye 
Disease Study 2 Research Group, 2013; SanGiovanni et al., 2008). The absence of 
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treatment options for dry AMD represents an area of urgent unmet medical need, and a 
major public health concern for the rapidly increasing elderly population. 
Risk Factors for AMD 
A number of population based cohort studies examined the relationship between 
AMD and a variety of possible risk factors. In 1992, the Age-Related Eye Disease Study 
(AREDS) Research Group enrolled participants with varying degrees of AMD severity in 
a study to understand the clinical course and prognosis of AMD. Since then, a number of 
epidemiological studies have provided insight into the complex interplay of genetic, 
environmental, metabolic, and demographic factors that have been shown to be 
associated with the development of AMD (E. Chew et al., 2014; Tomany et al., 2004). To 
illustrate these risk factors, data from the ten-year follow up of the AREDS cohort (E. 
Chew et al., 2014) as well as individual study data and pooled data from Tomany et al. 
(2004) that includes data from the 3 largest population based cohort studies (resulting in a 
pooled population of 9523 adults)- the Beaver Dam Eye Study (BDES, United States), 
the Blue Mountain Eye Study (Australia), and the Rotterdam Study (RS, Netherlands) 
will be used.  
Age. Age is commonly accepted risk factor for AMD as the presentation of the 
disease is uncommon before the fifth decade of life (Ryan, 2013). In the longitudinally 
followed AREDS cohort, age was an identified factor that increased the risk of 
developing late stage AMD over each 5-year period in the 65-69, 70-74, ≥75 age groups 
by 33%, 53%, and 86%, respectively as compared to the 55-64 age group (E. Chew et al., 
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2014). In the Blue Mountain Eye Study, age was strongly correlated with both late and 
early AMD (p<0.0001) (Joachim et al., 2015). Similar results were found in the BDES 
and RS studies (Klein et al., 2007; Smith et al., 2001).  
Genetics. Studies on concordance rates of AMD between monozygotic (MZ) and 
dizygotic (DZ) twins have shown that rates are double in those twins that originate from 
the same ovum (18% and 6% for MZ pairs and DZ twin pairs, respectively) (Seddon, 
Cote, et al., 2005). Models predict that heritability may account for 46% to 71% of the 
variability with AMD (Seddon, Cote, et al., 2005). AMD has also been shown to have a 
strong association with a number of genetic mutations (Edwards et al., 2005; Hageman et 
al., 2005; Haines et al., 2005; Jakobsdottir et al., 2005; Kanda et al., 2007; Klein, Myers, 
et al., 2013; Ratnapriya & Chew, 2013; Seddon et al., 2007; van Lookeren Campagne et 
al., 2014). AMD is most strongly associated with genes that code for CFH (Edwards et 
al., 2005; Hageman et al., 2005; Haines et al., 2005) and the ARMS2/HTRA1 gene 
(Kanda et al., 2007; Seddon et al., 2007). The human genome project has greatly added to 
the understanding of this disease by allowing for the ability to perform genome wide 
association studies (GWAS). A number of GWAS studies have independently confirmed 
genetic variation at the same CFH (Edwards et al., 2005; Hageman et al., 2005; Haines et 
al., 2005) and ARMS2/HTRA1 (Jakobsdottir et al., 2005; Rivera et al., 2005) coding 
regions. In a French cohort, those subjects with the high risk CFH polymorphism (OR, 
6.21) and those subjects with the high-risk ARMS2/HTRA1 (OR, 11.7) polymorphisms 
were associated with significantly higher risks of developing nAMD (Zerbib et al., 2014).  
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Smoking. In the early 1990’s researchers began to investigate the relationship 
between smoking and eye disease; in particular the association of smoking and AMD 
(Eye Disease Case-Control Study Group, 1992). In the pooled BDES, Blue Mountain Eye 
Study, and RS population, past smokers and current smokers were 5.52 and 6.19 times 
more likely to develop AMD compared to nonsmokers, respectively. In the AREDS 
cohort, current smokers had a 56% higher risk of advanced AMD versus nonsmokers (E. 
Chew et al., 2014). 
Inflammation. There is evidence that both the wet and dry forms of AMD are 
associated with an inflammatory process (Ambati & Fowler, 2012; van Lookeren 
Campagne et al., 2014). Excessive activation of inflammatory and immune responses 
within the retina, coupled with the retinal pigment epithelial and photoreceptor 
degeneration, is thought to result in activation of cells that produce complement 
components, pro-inflammatory cytokines, and growth factors resulting in increased 
angiogenesis and vascular permeability (Ambati & Fowler, 2012). Patients with AMD 
have been shown to elevate systemic inflammatory biomarkers such as c-reactive protein 
(CRP), interleukin-6 (IL-6), and homocysteine (Seddon, George, Rosner, & Rifai, 2005). 
Surgically excised choroidal neovascularization tissue in patients with nAMD has been 
shown to contain a number of different types of inflammatory cells (Submacular Surgery 
Trials Research Group, 2005). Dry AMD has been associated with activation of the 
complement System (Reynolds et al., 2009; Whitmore et al., 2015). The complement 
pathway is part of the body’s innate immune system that consists of a complex cascade of 
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serum proteins that interact to mount a defense against foreign pathogens. The 
complement cascade is activated via the classical (antibody-dependent), the alternative 
(antibody independent) and the lectin pathways. Local inflammation and activation of the 
complement cascade has been implicated in drusen formation, as the proteins of the 
complement pathway have been shown histologically to be a component of drusen (Wang 
et al., 2010). Furthermore, as stated previously, polymorphism in genes coding for 
complement or complement regulatory proteins have demonstrated increased risk in the 
development of AMD (Edwards et al., 2005; Haines et al., 2005; Klein, Myers, et al., 
2013; Triebwasser et al., 2015). 
Ethnicity. There are wide variations in the prevalence estimation of AMD and 
nAMD due to the heterogeneity of study populations and the use of different diagnostic 
criteria. However, there is a strong evidence suggesting that the prevalence of AMD, 
including nAMD, is much higher in the population of European ancestry than that in any 
other ethnicity (W. Wong et al., 2014). In the AREDS study there was a 183% higher risk 
of AMD in the Caucasian versus non-Caucasian populations (E. Chew et al., 2014). 
Among people of European ancestry, the annual incidence of late AMD is estimated to 
vary from 2.9 to 3.6 per 1,000 person-years (Buitendijk et al., 2013).  
Sex. AMD is predominantly present in the female population (Klein et al., 2011). 
In the AREDS study there was a 23% higher risk of AMD in women vs. men (E. Chew et 
al., 2014). In the RS study, an increased number of years between menarche and 
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menopause were associated with GA, suggesting that female sex hormones may play a 
minor role in disease progression (Tomany et al., 2004). 
Associated Disease. In a U.S. Medicare cohort, diagnosis of diabetic retinopathy 
(DR) significantly increased the risk of nAMD (Hahn, Acquah, Cousins, Lee, & Sloan, 
2013). Compared with non-diabetics, those with proliferative retinopathy were at a 
considerably higher risk (115%) than those with non-proliferative (68%) DR. However, 
having diabetes alone was not associated with an increased risk of developing nAMD. 
Obesity has been weakly associated with a higher risk of developing nAMD (Zerbib et 
al., 2014; Q. Zhang et al., 2016). 
Classification and Severity Scale of AMD 
Classification and severity scales for AMD have been developed based on 
findings from clinical examination and diagnostic imaging using fundus photography, 
fluorescein angiography, and optical coherence tomography (OCT). These scales range 
from a categorization of no aging changes present in the retina to late AMD, which 
includes choroidal neovascularization and geographic atrophy (Ferris et al., 2013; 
Nivison-Smith, Milston, Madigan, & Kalloniatis, 2014). Nivison-Smith et al. (2014) 
provide a detailed description of the Age-Related Eye Disease Study (AREDS) 
classification scheme that identifies clinical signs and pigmentary changes within the 
macula associated with progression of early AMD to late AMD. These grading scales are 
often used in clinical trials and epidemiological studies where masked grading of images 
are used to characterize the presence and/or extent of disease (Nivison-Smith et al., 
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2014). As this study will be using data from the masked grading of the 2005–2008 
NHANES survey period, the classification proposed by Klein et al. (1991) and adopted 
for the NHANES Digital Grading Protocol (CDC, 2005) to define early and late AMD 
will be employed. This will be detailed further in Chapter 3 in the explanation of study 
methodology section. The NHANES Digital Grading Protocol defined “early” AMD as 
the presence of either soft drusen with a grid area of greater than a 500 μm circle and the 
presence of retinal pigment epithelial depigmentation or increased retinal pigment or by 
the presence of soft drusen within the center 125 μm circle with the presence of retinal 
pigment epithelial depigmentation or increased retinal pigment in absence of signs of late 
AMD. “Late” AMD was defined by the presence of any of late lesions, such as GA, 
subretinal hemorrhage or visible subretinal new vessels, PED/retinal detachment, 
subretinal fibrous scar or laser treatment scar, or self-reported history of photodynamic or 
anti–vascular endothelial growth factor treatment for exudative AMD (Klein et al., 2011).  
AMD Epidemiology 
Globally, 8.7% of all cases of blindness are attributed to AMD (W. Wong et al., 
2014), a majority of which can be found in developed nations. The United Nations (UN) 
reports that population ageing is taking place in nearly all countries throughout the world 
resulting from decreasing mortality and declining fertility (United Nations, 2013). Similar 
trends are seen in the United States as the Census Bureau suggested that the number of 
Americans over 65 years of age will more than double to 87 million by the middle of this 
century (United States Census Bureau, 2015a). AMD prevalence in the United States is 
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estimated to double by 2050 from 2.07 to 5.44 million patients (NEI, 2016b). The global 
prevalence of early, late, and any AMD were shown in a meta-analysis of population-
based studies to be to be 8.0%, 0.37%, and 8.7%, respectively (W. Wong et al., 2014). As 
seen in other multi-ethnic studies, the highest prevalence of AMD was found in the 
people of European ancestry at 0.50% followed by Asian and Hispanic ethnicities. The 
AMD prevalence rate is lowest among people of African ancestry at 0.28% (W. Wong et 
al., 2014).  
Wong et al. (2014) estimated that by 2020, 11.26 million patients will be 
diagnosed with late AMD, and the current prevalence of 9.64 million will nearly double 
to 18.57 million within next 25 years. Due to global trends in population growth, 
maximum prevalence increase will be seen in Asia, followed by Europe. In Asia, the 
prevalence of late AMD is likely to increase from 4.59 million patients in 2014 to 9.92 
million in 2040, whereas in Europe, the prevalence is projected to increase from 2.57 
million to 3.69 million during the same time period (W. Wong et al., 2014).  
There is some variation in the prevalence estimates of AMD and nAMD due to 
the heterogeneity of study populations and the use of different diagnostic criteria. Klein et 
al. (2011) reported that the overall prevalence of AMD in the 40 and older population of 
the United States based on the NHANES survey was 6.5%. Late AMD (choroidal 
neovascularization and geographic atrophy) was present in 0.8% of the population. The 
disease varies by ethnicity, and was shown to be present 7.3%, 2.4%, and 5.1% of non-
Hispanic Whites, non-Hispanic Black, and Mexican Americans, respectively (Klein et al., 
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2011). As the NHANES survey draws from predominantly Caucasian respondents, the 
prevalence numbers may not accurately represent other ethnic groups. In the Los Angeles 
Latinos Eye Study (LALES) the adjusted prevalence of AMD was 10.2% with late AMD 
present in 0.52% of the Latino population. The Multi-Ethnic Study of Atherosclerosis 
(MESA) aimed to study the incidence of AMD and associated risk factors in White, 
Black, Hispanic, and Chinese residents of the United States (Fisher et al., 2016). Subject 
retinal photography data was collected 8 years apart to look for signs of early and late 
AMD. The incidence of early and late AMD was 4.1% and 2.3%, respectively. Consistent 
with other studies of AMD, incidence of early and late AMD was highest in Whites 
(5.3% and 4.1%, respectively), followed by Chinese (4.5% and 2.2%, respectively), 
Hispanics (3.3% and 0.8%, respectively), and lowest in Blacks (1.6% and 0.4%, 
respectively) (Fisher et al., 2016). 
SDB 
SDB is defined by the American Academy of Sleep Medicine as a constellation of 
conditions that includes central sleep apnea (CSA), OSA, and sleep-related 
hypoventilation or hypoxemic syndromes (American Academy of Sleep Medicine, 2014). 
During SDB patients experience periods of apnea (breathing cessation) and hypopnea 
(periods of shallow breathing). The public health impact of SDB is significant, as the 
disease has been implicated as a risk factor for a number of chronic diseases including 
cardiovascular disease, obesity, diabetes, and depression (CDC, 2016b). Each of these 
diseases is associated with a significant morbidity and mortality profile and responsible 
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for much of the chronic disease burden in the United States (Bauer, Briss, Goodman, & 
Bowman, 2014). Long-term consequences of SDB include reduced quality of life 
(Batool-Anwar et al., 2016), cognitive impairment (Osorio et al., 2015), increased risk of 
motor vehicle accidents (Basoglu & Tasbakan, 2014); cerebrovascular (Arzt, Young, 
Finn, Skatrud, & Bradley, 2005), cardiovascular (Kendzerska, Gershon, Hawker, Leung, 
& Tomlinson, 2014), and metabolic disease (Kawada et al., 2015); and increased 
mortality (Kendzerska et al., 2014). 
The gold standard for diagnosing and monitoring SDB and OSA is a 
polysomnography (PSG) examination, otherwise known as a “sleep study” (Epstein et al., 
2009). During the sleep study, patients are monitored for events where there is cessation 
of breathing or shallow breathing as well as changes in brain activity, blood oxygen level, 
heart rate and eye/leg movements. This is most often done in a clinical setting over the 
course of one or more nights by highly trained staff. Home sleep monitoring devices are 
available, although reliability is poor compared to PSG and misclassification is possible 
(Aurora, Swartz, & Punjabi, 2015).  
Current front-line treatment for moderate to severe OSA and SDB is the use of 
CPAP, a device that consists of an air pump connected to a hose/mask apparatus that is 
fitted to the face of the patient with SDB (Epstein et al., 2009). Air is forced through the 
hose/mask under positive pressure and forces open the upper airway, allowing for 
improved oxygenation in the lungs. CPAP has been shown to be highly effective in 
improving objective measures of SDB in a number of randomized clinical trials 
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(McMillan et al., 2014; T. Young et al., 1993). The effects of CPAP therapy are not 
limited to improving objective measures of SDB, but have been shown to improve 
cognitive functioning (Aaronson et al., 2016), glucose metabolism (Pamidi et al., 2015; 
Salord et al., 2016), cholesterol profile (McMillan et al., 2014), and cardiovascular 
outcomes (Marin, Carrizo, Vicente, & Agusti, 2005). Unfortunately, CPAP has been also 
found to be a notoriously non-compliant treatment modality (Weaver & Grunstein, 2008). 
Participants in clinical trials with low compliance do not attain the same results seen in 
those studies that utilize the device as prescribed. A number of recent trials have shown 
that real world initiation of CPAP therapy does not reduce oxidative stress (as measured 
by cardiovascular stress/inflammation biomarkers) or reduce long-term adverse 
cardiovascular outcomes (Paz et al., 2016; Peker et al., 2016). Once the data are adjusted 
for compliance to CPAP treatment, the reduction in inflammatory biomarkers from 
therapy becomes significant (Paz et al., 2016). 
There are other treatment options for the patient with SDB including mandibular 
advancement devices (MAD) (oral appliances) that are worn in the mouth during sleep to 
attempt to mechanically open the upper airway by pushing the jaw forward (D. Young & 
Collop, 2014). Surgical interventions are available to patients with SDB, although they 
are highly invasive as compared to MAD or CPAP. Surgical intervention remains a 
second line treatment for moderate to severe OSA, even in light of the data illustrating 
that uvulopalatopharyngoplasty (UPPP) and maxillomandibular advancement (MMA) 
surgeries have shown statistically significant improvements in AHI (D. Young & Collop, 
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2014). A number of other strategies should be employed to combat SDB including 
diet/weight loss, increase in amount of exercise, and sleep posture regardless of 
CPAP/MAD/surgical approaches. Weight loss (Peppard, Young, Palta, Dempsey, & 
Skatrud, 2000) and increased exercise (Mendelson et al., 2016) have shown to improve 
objective measures of SDB. To date pharmacotherapy for SDB has not proven to be an 
effective treatment modality (Jordan, McSharry, & Malhotra, 2014).      
Classification and Severity Scale of SDB  
During the PSG examination, oxygen saturation of the blood is monitored. 
Shallow breathing causing reductions in blood oxygen saturation are termed hypopneas. 
Apnea is defined as a complete pause in breathing lasting at least 10 seconds during sleep 
(Epstein et al., 2009). By counting the number apneas and hypopneas in an hour of sleep, 
one can derive the apnea-hypopnea index (AHI), a categorical measure of OSA/SDB. 
The AHI is categorized in most of the currently published studies according to the 
following consensus cutoff points illustrated in Table 1 (Epstein et al., 2009). 
Table 1 
Apnea-Hypoapnea Index (AHI) Severity Categories for OSA 
Category AHI 
Normal 0 
Minimal OSA > 0 to ≤ 5 
Mild OSA 5 to ≤ 15 
Moderate OSA 15 to ≤ 30 
Severe OSA ≥ 30 
Note: Adapted from Epstein et al. (2009) 
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Risk Factors Associated with SBD 
Anatomy. OSA syndrome is defined as a condition where there are repeated 
episodes of complete or partial blockage of the upper airway during sleep (Jordan et al., 
2014). There are a number of anatomical factors that lead to a restricted airway 
associated with OSA/SDB (Schwab et al., 2003). These include decreased size of the 
airway lumen, enlarged tonsils, craniofacial anatomy abnormalities (retrognathia for 
example), tongue volume, and body fat in the neck area surrounding the airway. These 
anatomical changes contribute to airway collapse during sleep. A number of upper airway 
muscles that are aroused during wakefulness and become relaxed during sleep have also 
been implicated as a causative factor (Mezzanotte, Tangel, & White, 1992). Inflammation 
of the upper airway due to environmental exposures such as smoking or chronic sinusitis 
can also play a role in SDB (Peppard et al., 2013; T. Young, Peppard, & Gottlieb, 2002). 
Obesity. Obesity is a major risk factor for SDB, a significant public health 
concern as much of the United States population is considered overweight (Franklin, 
Sahlin, Stenlund, & Lindberg, 2013; Heinzer et al., 2015; Peppard et al., 2013). A 
number of studies have shown that weight loss, even in morbidly obese individuals 
undergoing gastric bypass surgery can improve symptoms of SDB (Barvaux, Aubert, & 
Rodenstein, 2000; Grunstein et al., 2007). 
Age. SDB does not seem to be as prevalent in both young and elderly patients and 
has been shown to peak in the 45-64 year-old age group (Bixler et al., 1998). This 
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phenomenon of increasing prevalence of OSA with age and then a reduction in cases 
after age 60 was found in both men and women in the Wisconsin Sleep Cohort Study (T. 
Young et al., 1993). This phenomenon may be partially explained by unreliable results 
from the smaller sample of elderly participants represented in the study population. Many 
SDB studies choose working age populations as their sample, and therefore the elderly 
population is under sampled. These results were not found in a study of women in 
Sweden where participants were selected from the general population without bias for 
selecting certain age categories. In this study OSA was found in 24% (95% CI: 45–55%) 
of females aged 20–44 years, in 56% (95% CI: 47–65%) of females aged 45–54 years 
and in 75% (95% CI: 67–82%) of females aged 55–70 years (Franklin et al., 2013). 
Gender. SDB is generally two times more prevalent in men than in women (Ip, 
Lam, et al., 2004; Kim et al., 2004; T. Young et al., 1993).  
Smoking. Analysis of participants from the Wisconsin Sleep Cohort Study 
indicate that compared with those that have never smoked, current smokers had a 
significantly greater risk of moderate or worse SDB (OR, 4.44) (Wetter, Young, Bidwell, 
Badr, & Palta, 1994). In a study of 964 patients that were former and current smokers 
referred to an outpatient sleep clinic there was a statistically significant association with 
younger age of onset and severity of OSA (Varol, Anar, Tuzel, Guclu, & Ucar, 2015). 
Results to the contrary have been reported from a University Hospital sleep clinic study 
of over 3,000 men (Hoflstein, 2002). In the study logistic regression revealed that heavy 
smokers (>30 pack years) had approximately twice the risk of having AHI >50 compared 
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to nonsmokers, although the OR was <1.0 after adjusting for age, BMI, and gender 
(Hoflstein, 2002).  
Alcohol. Alcohol use as a risk factor is inconclusive as it was studied as a variable 
in a number of epidemiological studies and an association was noted in some, but not 
found in others (Peppard, Austin, & Brown, 2007; Udwadia, Doshi, Lonkar, & Singh, 
2004). In the Wisconsin Sleep Cohort study, men who consumed more alcohol had 25% 
greater odds of mild or worse SDB (OR = 1.25, 95% CI: 1.07-1.46, p = 0.006). For 
women, alcohol consumption was not significantly associated with increased risk of SDB 
(Peppard et al., 2007). 
The Association of SDB and CVD 
SDB is associated with a number of cardiovascular and cerebrovascular diseases 
(Arzt et al., 2005; Kendzerska et al., 2014; Marin et al., 2005; Redline et al., 2010) 
including hypertension (Nieto et al., 2000; O'Connor et al., 2009), and coronary heart 
disease (CHD) (Drager et al., 2010; Gottlieb et al., 2010; Hla et al., 2015). As AMD is a 
disease of the microvasculature it is important to understand the impact of SDB on the 
cardiovascular system. Drager et al. (2010) have illustrated that SDB may be present in 
>50% of subjects with hypertension. There is a strong scientific rationale as to why SDB 
may be related to hypertension as the vascular endothelium may be sensitive to the 
repeated decreased oxygen levels that occur in subjects with SDB (Ip, Tse, Lam, Tsang, 
& Lam, 2004). Theoretical mechanisms include SDB causing endothelial cell dysfunction 
and increased activation of the sympathetic nervous system, both of which have been 
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cited as underlying causality (Ip, Tse, et al., 2004). The same underlying disease process 
may be at play with AMD as the vascular endothelium in the eye is subject to the same 
stressors as the systemic circulation and associations with AMD and hypertension have 
been reported (Hyman, Schachat, He, & Leske, 2000).     
Two population-based studies have provided important data on the impact of 
sleep apnea in the United States. The Sleep Heart Health Study (SHHS) is a prospective 
cohort study of the cardiovascular consequences of OSA (Quan et al., 1997). The 
Wisconsin Sleep Cohort is a stratified random sample from the year 1988 that includes 
state employees in Wisconsin between 30 and 60 years old (T. Young et al., 1993). In one 
of the seminal publications to investigate the association of SDB and hypertension, Nieto 
et al. (Nieto et al., 2000) performed a cross-sectional analysis of the SHHS. The primary 
exposure in this study was measured by AHI and the outcome of interest was 
hypertension (blood pressure >140/90) (Nieto et al., 2000). In this study prevalence of 
hypertension increased significantly with increasing SDB measures, although the authors 
point to the fact that at least some of the association was explained by body mass index 
(BMI). After adjusting for potential confounding variables, the OR for hypertension, 
comparing the highest category of AHI (AHI >30) with the lowest category (AHI<1.5), 
was 1.37 (95% confidence interval [CI, 1.03-1.83; P=.005)] (Nieto et al., 2000). 
O’Connor et al. (2009) reported on the association of hypertension with SDB (AHI<5) in 
the SHHS. In this study, the odds ratio (OR) for hypertension increased in relation to 
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increasing baseline AHI. Although the authors conclude that much of the relationship can 
be accounted for by baseline BMI (O'Connor et al., 2009).  
Kenderska et al. (Kendzerska et al., 2014) performed a retrospective cohort study 
using a clinical database from major academic institution in Canada looking at the impact 
of SDB on a composite CVD outcome (myocardial infarction, stroke, congestive heart 
failure, revascularization procedures, or death from any cause). Cox regression models 
were used to analyze the association between baseline OSA and the composite outcome, 
while controlling for traditional risk variables. AHI was significantly associated with 
event-free survival in univariate analyses when treated as a continuous predictor in their 
model [HR= 1.49, 95% CI: 1.42–1.57; p<0.001] (Kendzerska et al., 2014). Even after 
controlling for a number of CVD risk factors (age, sex, smoking status, BMI, AHI) the 
association between AHI as a continuous variable and the composite outcome of 
remained statistically significant (HR= 1.12; 95% CI: 1.05–1.2, p<0.001). 
Yeboah et al. (Yeboah et al., 2011) investigated the association between OSA and 
CVD in the Multi-Ethnic Study of Atherosclerosis (MESA) cohort. The sample for this 
study included 6814 men and women aged 45–84 years old from United States 
communities with diverse ethnic backgrounds. This provided a population that consisted 
of participants who were 38% White, 28% Black, 22% Hispanic, and 12% Chinese 
(Yeboah et al., 2011). The primary exposure in this study was AHI and the outcome of 
interest was CVD events (defined as CVD events that were adjudicated by a committee 
of physicians). When compared healthy participants, those with OSA were associated 
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with high CVD event rates in both univariate and multivariate models [hazard ratio 
(95%); 1.89(1.22–2.93), p = 0.004 and 1.91(1.20–3.04), p = 0.007, respectively] (Yeboah 
et al., 2011). 
SDB and CVD 
Marshall et al. (2014) studied 400 participants in Australia to investigate as to 
whether SDB increased the risk of stroke, all-cause mortality, CVD, and CHD. The 
primary exposure in this study was the respiratory disturbance index (RDI) and the 
outcome of interest was the prevalence of ischemic stroke (Marshall et al., 2014). OSA 
severity was quantified at a single night portable home PSG in 1990 and then participants 
were followed up in 2010. Moderate-severe OSA was statistically associated with all-
cause mortality (HR = 4.2; 95% CI 1.9, 9.2) and stroke (3.7; 1.2, 11.8), but not associated 
with CVD (1.9; 0.75, 4.6) or CHD incidence (1.1; 0.24, 4.6) (Marshall et al., 2014). The 
authors comment that although the prevailing thought is that sleep apnea is thought to 
increase mortality through cardiovascular disease, the association was not statistically 
significant in this study (Marshall et al., 2014).  
The SHHS study showed a significant positive association between stroke and 
AHI was in men (p=0.016) (Redline et al., 2010). Men in the highest AHI quartile (>19) 
had an adjusted hazard ratio of 2.86 (95% confidence interval, 1.1–7.4). In the mild to 
moderate range (AHI, 5–25), each one-unit increase in AHI in men was estimated to 
increase stroke risk by 6% (95% confidence interval, 2–10%). In women, stroke was not 
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significantly associated with AHI, but there was an increased risk observed when the AHI 
was > 25 (Redline et al., 2010).  
Arzt et al. (Arzt et al., 2005) performed cross-sectional, longitudinal analyses on 
subjects from the Wisconsin Sleep Cohort. The primary exposure in this study was 
measured by AHI and the outcome of interest was stroke. In the study, participants with 
an AHI of ≥20 or greater had increased odds for stroke (OR=4.33; 95% confidence 
interval, 1.32– 14.24; p <0.02) compared with those without SDB (AHI <5) after 
adjustment for known confounding factors (Arzt et al., 2005).  
The previous studies illustrated association between OSA and stroke, although 
their patient population represented middle-aged persons that may not be representative 
of the elderly population. To investigate whether OSA is associated with stroke in this 
population, Munoz et al. (2006) performed a prospective longitudinal study in elderly 
subjects from Spain. The primary exposure in this study was measured by AHI and the 
outcome of interest was stroke (Munoz et al., 2006). In subjects with severe OSA 
(defined as AHI > 30) at baseline had a statistically significant risk of stroke  (hazard 
ratio= 2.52, 95% CI= 1.04 to 6.01, P= 0.04) (Munoz et al., 2006). 
SDB and CHD 
Hla et al. (2015) reported findings from the Wisconsin Sleep Cohort Study on the 
association of CHD and SDB. This study investigated 1,131 adults over the age of 30 
who completed one or more overnight sleep studies, which were free of CHD baseline, 
and were not treated by CPAP. Participants were then followed longitudinally for 24 
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years. The primary exposure in this study was measured by AHI and the outcome of 
interest was CHD or heart failure (HF) (Hla et al., 2014). Participants with untreated 
severe SBD (AHI > 30) were 2.6 times more likely to have CHD or heart failure 
compared to those without SDB (Hla et al., 2015). 
Gottlieb et al. (2010) reported an association of CHD with SDB in the SHHS. In 
their study, they investigated 1927 men and 2495 women >40 years of age and free of 
coronary heart disease and heart failure at the time of study entry (Gottlieb et al., 2010). 
Subjects were followed for a median of 8.7 years. The primary exposure in this study was 
measured by AHI and the outcome of interest was CHD (Gottlieb et al., 2010). OSA was 
shown to be a significant predictor of CHD only in men ≤70 years of age (adjusted 
hazard ratio 1.10 [95% confidence interval 1.00 to 1.21] per10-unit increase in apnea-
hypopnea index [AHI]) but not in men >70 or in women of any age. In men age 40 to 70 
years old, those participants that had AHI >30 were 68% more likely to develop CHD 
than those with AHI <5 (Gottlieb et al., 2010).    
SDB Epidemiology 
As with AMD, the estimated prevalence numbers for SDB have a broad range, 
likely based on the methodology and definitions for determining the presence of disease 
(Franklin et al., 2013; Heinzer et al., 2015; Peppard et al., 2013; T. Young et al., 1993). 
One of the highest prevalence estimates comes from Franklin et al. (2013) in a study of 
OSA in a Swedish population-based random sample of 10,000 women. The authors 
report that OSA (defined as AHI ≥5) occurs in 50% (95% CI 45–55%) of females aged 
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20–70 yrs. 20% of females have moderate (defined as AHI 15-<30) and 6% severe sleep 
apnea (defined as AHI ≥30). In those participants 55-70 years old or with a BMI ≥ 30 
kg/m2 severe sleep apnea was present in 14% (95% CI 8.1–21%) and 31% (95% CI 12–
50%) of the population, respectively (Franklin et al., 2013). The higher estimates in this 
study may be due to the fact that home PSG was used to measure AHI and the 
measurement was not performed in a standardized clinical setting. 
Heinzer et al. (2015) studied a population of 3043 participants in Lausanne, 
Switzerland. Participants were examined with PSG in a University Hospital setting and 
moderate to severe SDB was defined as AHI ≥15. The prevalence of moderate-to-severe 
SDB was 23.4% (95% CI: 20.9–26.0) in women and 49.7% (95% CI: 46.6–52.8) in men. 
There was a statistically significant difference across all categories of SDB based on 
those <60 versus ≥60 and men vs. women (Heinzer et al., 2015).  
The Wisconsin Sleep Cohort Study estimated the prevalence of OSA in a random 
sample of 3,513 US employees in Wisconsin ages 30-60 years (T. Young et al., 1993). 
Participants were observed during an overnight PSG examination. The estimated 
prevalence of SDB (defined as AHI ≥5) was 9% for women and 24% for men. Peppard et 
al. (2013) investigated this same population during the periods of 1988–1994 and 2007–
2010. The authors estimate moderate to severe SDB (AHI ≥15) are 10% (95% CI: 7-12) 
among 30–49-year-old men; 17% (95% CI: 15-21) among 50–70-year-old men; 3% (95% 
CI: 2, 4) among 30–49-year-old women; and 9% (95% CI: 7, 11) among 50–70 year-old 
women (Peppard et al., 2013). These results indicate that over the two decade study 
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period, there was between a substantial increase in SDB in the U.S. population (Peppard 
et al., 2013).  
A number of epidemiological studies have been performed in populations that 
predominantly consist of ethnicities other than Caucasian. In a study of middle age Indian 
men, the prevalence of OSA was 19.5% (Udwadia et al., 2004). In a population-based 
sample from Korea, the prevalence of SDB was 27% and 16% in men and women, 
respectively (Kim et al., 2004). In a study of middle-aged Chinese men and women living 
in Hong Kong the prevalence of SDB was 8.8% and 3.7%, respectively (Ip et al., 2001; 
Ip, Lam, et al., 2004).  
AMD and SDB  
As humans age, there is evidence that the quality of sleep deteriorates (Bloom et 
al., 2009). Changes in circadian rhythms, the sleep–wake cycle, and decreased synthesis 
of melatonin may all contribute to this phenomenon (Bloom et al., 2009; Rosen et al., 
2009). There is clear evidence that SDB is associated with the development of 
cardiovascular (Laaban et al., 2002; Lavie, Herer, & Hoffstein, 2000; Nieto et al., 2000; 
Peker, Hedner, Kraiczi, & Loth, 2000; Peppard, Young, Palta, & Skatrud, 2000; Shahar 
et al., 2001; Stone et al., 2016) and neurodegenerative diseases (Buratti et al., 2014; 
Osorio et al., 2015; Yaffe, Nettiksimmons, Yesavage, & Byers, 2015). Experimentally, it 
has been demonstrated that apnea leads to neuronal damage (apoptosis) in susceptible 
regions of the brain (Fung, Xi, Zhang, Sampogna, & Chase, 2012; J. H. Zhang, Fung, Xi, 
Sampogna, & Chase, 2009). 
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One common mechanism that has been proposed to describe this relationship 
between SBD and both cardiovascular and neurodegenerative diseases is vascular 
impairment (Buratti et al., 2014). Similarly, vascular impairment has been proposed as a 
possible mechanism for AMD pathogenesis (Boltz et al., 2010; Grunwald et al., 2005; 
Remsch et al., 2000). Based on the high-energy demand of human retina, nature has 
provided it with one of the greatest blood flow networks of any organ in the human body 
relative to its size (Ames et al., 1992; Blasiak et al., 2014; Boltz et al., 2010; Remsch et 
al., 2000; Sim & Fruttiger, 2013). This places the outer retina, which is avascular but 
highly metabolic, in a vulnerable state when there is insufficient energy and low 
oxygenation of the blood stream.  
The eye allows researchers the ability to investigate microvascular changes in a 
non-invasive manner, therefore providing a window on the health of the systemic 
vasculature. Retinal arterioles are shown to be anatomically similar to cerebral and 
coronary arterioles, and systemic disease can often be diagnosed from ophthalmic 
examination or through the use of diagnostic techniques such as fundus photography, 
fluorescein angiography, and optical coherence tomography (OCT) (Klein, Klein, & 
Moss, 1997; T. Wong et al., 2001). In both the CHS and ARIC study cohorts, retinal 
microvascular abnormalities are strongly and independently associated with hypertension 
as evident by arteriolar narrowing (as measured by the arteriovenous ratio [AVR]) and 
arteriovenous nicking (Sharrett et al., 1999; T. Wong et al., 2002). Although there is a 
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significant relationship, it is unclear whether AVR and/or arteriovenous nicking are an 
appropriate measure of disease. 
Microvascular changes have been shown to be associated with SDB in the Multi-
Ethnic Study of Atherosclerosis (MESA) study (M. Chew et al., 2016). Women that were 
enrolled in the MESA study showed an association between SBD and narrower arterioles 
[regression coefficient (β)= -5.76; 95 % CI: -8.51, -3.02] after adjusting for cardio-
metabolic risk factors. Although in men there was no association between SDB and 
arteriolar caliber, there was an association with incident CVD (M. Chew et al., 2016). 
The authors proposed that there may be a potential gender difference in the susceptibility 
to microvascular disease in association with SDB (M. Chew et al., 2016).  
Boland et al. (2004) performed a sub study of the Sleep Heart Health Study 
(SHHS) that examined the relation between SDB (as measured by RDI) and retinal 
microvascular abnormalities. The SHHS is a prospective cohort design study consisting 
of subjects 40 years and older to investigate the association of SDB with cardiovascular 
disease (Quan et al., 1997). The authors found that the overall prevalence of retinopathy 
was slightly higher in people with higher RDI values, although after adjustment for age, 
body-mass index, hypertension, diabetes, and other factors, the association no longer 
held. The authors concluded that the weak association with SDB and early microvascular 
dysfunction should be investigated further.  
Boltz et al. (2010) tested the hypothesis that lower retinal blood flow (inducing a 
hypoxic environment within the retina) may be associated with an increased risk of 
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developing choroidal neovascularization in an observational longitudinal study. Their 
research indicated that lower retinal blood flow had a statistically significant association 
with progression to choroidal neovascularization. This supports the hypothesis that the 
hypoxic environment created by SDB may also have an effect on the progression of 
AMD.  
In addition to the retina allowing for insight into microvascular changes in the 
body, neurodegenerative changes in the eye have can also be examined, quantified, and 
imaged non-invasively in individuals with SDB (Huseyinoglu et al., 2014; Shiba et al., 
2014; Xin, Wang, Zhang, Wang, & Peng, 2014). Huseyinoglu et al. (2014) investigated 
101 subjects with OSA and 20 controls without OSA using OCT to look at impact on the 
retina nerve fiber layer (RNFL). The researchers performed PSG and ophthalmologic 
examination including visual field (VF) testing. Subjects were graded based on PSG 
score and placed into mild, moderate, and severe OSA categories. The researchers found 
that there was a significant reduction in RNFL thickness in the subjects with severe OSA 
compared with the other categorized groups. Shiba et al. (2014) corroborated these 
findings in a study of 124 consecutive subjects who underwent PSG and OCT to measure 
RNFL thickness, foveal thickness, and total macular volume. Their findings indicate that 
the RNFL thickness was correlated with higher AHI values (Shiba et al., 2014). PSG 
findings were not correlated with foveal thickness or total macular volume. These 
findings have been corroborated in other research studies illustrating that thinning of the 
retina and choroid occurs with increasing OSA severity (Xin et al., 2014). Similar to the 
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aforementioned retinal findings, multiple studies investigating the morphological changes 
in brains of subjects with OSA have shown that the volume of cortical gray matter is 
smaller in patients with OSA as compared to controls (Branger et al., 2016; Morrell et al., 
2003; Torelli et al., 2011; Yaouhi et al., 2009). 
Another important pathological finding that is shared by subjects with AMD or 
SDB is the accumulation of amyloid-beta (Aβ) in the retina (Mullins et al., 2000; Ohno-
Matsui, 2011; Ratnayaka, Serpell, & Lotery, 2015) and brain, respectively (Branger et al., 
2016; Sprecher et al., 2015). Retinal ganglion cells (RGC) and the retinal pigment 
epithelial layer have been identified as a source Aβ deposition within the retina as a 
component of drusen (Ohno-Matsui, 2011). Amyloid plaques in the brain have been 
shown to be a hallmark of Alzheimer’s disease (Jack et al., 2013). Branger et al. (2016) 
have illustrated that Aβ accumulation in the brain, as assessed by structural MRI and 
florbetapir-PET scans, was associated with worse self-reported sleep quality. Sprecher et 
al. (2015) found similar results in participants enrolled in the Wisconsin Registry for 
Alzheimer’s Prevention (WRAP). Results illustrated that participants with the perception 
of less adequate sleep, more sleep problems, and greater somnolence had a greater brain 
amyloid burden (Sprecher et al., 2015). In this study, Aβ was not associated with reported 
sleep amount, symptoms of SDB, trouble falling asleep, or the Epworth Sleepiness Scale 
(ESS) score (Sprecher et al., 2015). This phenomenon has been noted in other studies 
imaging Aβ deposition in the brain of those with symptoms of SDB (Spira et al., 2014).  
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As stated by Blasiak et al. (2014) “it is hard to determine whether any particular 
pathology is linked with the stress caused by a risk factor or if it is a consequence of the 
pathology or a combination of both”. Oxidative stress is defined as an imbalance with the 
production of reactive oxygen species (ROS) and antioxidant defenses against those free 
radicals (Betteridge, 2000). Cells have the ability to combat free radicals in most acute 
situations, although in chronic situations tissue damage can ensue that may be irreversible 
(Blasiak et al., 2014). The retina is constantly producing waste products from the 
reactions that transpire when light energy causes photochemical reactions with the 
photoreceptors. The retina has innate mechanisms of autophagy (intracellular mechanism 
of waste removal) to remove these waste products by the retinal pigment epithelial layer. 
Blasiak et al. (2014) proposes that any event that impairs blood flow to the retina or 
reduces retinal oxygenation (SDB, smoking, COPD for example) will induce hypoxia 
thus impairing the normal autophagy function within the retina, resulting in the build-up 
of waste products. This build-up of waste products in AMD (drusen for example) can 
cause a mechanical impairment of the transmission of signals from photoreceptors to the 
appropriate processing centers in the brain (Blasiak et al., 2014). Oxidative stress has 
been implicated as the cellular mechanism by which smoking is associated with AMD 
(Marazita, Dugour, Marquioni-Ramella, Figueroa, & Suburo, 2015). Marazita et al. 
(2015) demonstrated that exposure of human retinal pigment epithelial cells to a cigarette 
smoke concentrate enhanced ROS levels and caused DNA damage. In their experiment, 
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interleukin-6 (IL-6), IL-8, and VEGF levels were increased and CFH expression was 
downregulated (Marazita et al., 2015).  
SDB and Treatment for AMD 
SDB has also been shown to interfere with current anti-VEGF treatments for 
neovascular AMD. Barak et al. (2012) analyzed the functional and anatomical response 
to treating choroidal neovascularization with anti-VEGF therapy with Avastin® in 
patients before and after treatment of OSA. Untreated OSA in this study hampered the 
response to anti-VEGF therapy for the treatment of neovascular AMD. After CPAP 
therapy, the anatomical improvement provided by anti-VEGF treatment was evident, 
although functional vision improvement did not follow. Nesmith, Ihnen and Schaal 
(2014) looked at 103 patients with AMD compared to age-matched controls with regard 
to treatment response to anti-VEGF therapy. Symptoms associated with OSA were 
collected using the Berlin Questionnaire (BQ). The authors found that 30% of subjects 
with AMD that had a poor response to anti-VEGF therapy were at a significantly higher 
risk of OSA as assessed by the BQ (p< 0.05) (Nesmith et al., 2014). 
SDB Associations with AMD 
Recently, a number of studies have looked at whether sleep-associated variables 
are associated with AMD (Keenan et al., 2016; Khurana et al., 2016; Perez-Canales et al., 
2016). Khurana et al. (2016) administered a prospectively designed sleep history 
questionnaire to 1,003 consecutive patients in a private retina practice. Participants were 
graded and placed into categories of no AMD, early AMD, nAMD, or geographic 
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atrophy using the modified Wisconsin Age-Related Maculopathy Grading System. Using 
multivariate analysis (controlling for age, gender, and smoking history), sleep hours were 
not associated with nAMD (p = 0.97) as compared to controls. Sleeping >8 hours was 
associated with GA (p = 0.02) when compared with patients without AMD (age-adjusted 
OR=7.09; 95% confidence interval, 1.59–31.6) (Khurana et al., 2016). The strength of 
this study is a large sample size as well as grading of retinal findings from fundus 
photographs. One of the weaknesses of the study is the questionable generalizability as 
all subjects were recruited from one clinic located in one geographic area.  
Perez-Canales et al. (2016) performed a case control study that found a 
statistically significant association between sleep duration and AMD (for <6 hours, 
OR=3.29, 95% confidence interval 1.32–8.27; for 6–7 hours, OR= 2.25, 95% CI 0.80–
6.32; and for >8 hours, OR=1.39, 95% CI 0.53–3.73) compared with the reference 
category of 7–8 hours. In addition, the highest utilization of sleep medication was being 
used in the population with AMD (p < 0.001). The results of the study remained 
statistically significant after adjustment for smoking status, history of depression, regular 
physical activity, BMI and hypertension (Perez-Canales et al., 2016). This trend towards 
a higher risk of nAMD in subjects with both short and long sleep duration when 
compared with those in the 7–8 hours group suggests a possible U-shaped relationship 
between sleep duration and nAMD (Perez-Canales et al., 2016). This study did not 
investigate the association of sleep duration and GA.  
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Keenan et al. (2016) linked English national hospital episode statistics (HES) for 
248,408 patients with AMD that were admitted to English National Health Service 
(NHS) treatment facilities and also had OSA. Their results showed that OSA was 
positively associated with AMD (Keenan et al., 2016). The authors accounted for obesity 
as a potential confounder in the analysis, although it had little effect on the association. 
The strength of this study is that it includes a large number of participants from a major 
healthcare system, although as with many of the other studies AMD severity was not 
categorized. 
Several studies have documented the association between SDB and other 
ophthalmological diseases, including nonischemic anterior optic neuropathy, 
chorioretinopathy, floppy eyelid syndrome, primary open-angle glaucoma, normal-
tension glaucoma, and papilledema. There are several studies showing association 
between SDB and glaucomatous changes in the optic nerve characterized by optic nerve 
head changes (Casas et al., 2013), visual field defects, and RNFL thickness (Casas et al., 
2013; Ferrandez et al., 2016; Lin et al., 2011) in light of the intraocular pressure (IOP) 
being normal. 
Confounders 
AMD and SDB share similar potential confounders that include age, gender, 
obesity, and past and current smoking status. Age is the most strongly associated risk 
factor for AMD and in concert with obesity is the most important risk factor for SDB. 
SDB has been shown to reach peak prevalence in the 45-64 year old age group (Bixler et 
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al., 1998), while AMD has been shown to increase in prevalence with increasing age (E. 
Chew et al., 2014; Tomany et al., 2004). Gender is a potential confounder in both 
diseases as with AMD there is a slightly higher prevalence in women (E. Chew et al., 
2014; Tomany et al., 2004), whereas SDB is more prevalent in men (Heinzer et al., 2015; 
Peppard et al., 2013). There have been reports that menopausal status may influence the 
prevalence estimates of SDB and this same confounding has been suggested with AMD 
(Bixler et al., 2001; Tomany et al., 2004). Obesity is strongly associated with SDB, 
whereas the association with AMD is weak (Q. Zhang et al., 2016). In studies of SDB 
and AMD where obesity was taken into account as a confounder, the effect on the 
association was minimal (Keenan et al., 2016). Smoking is strongly associated with both 
AMD (E. Chew et al., 2014) and SDB (Varol et al., 2015). In both diseases, smoking is 
associated with earlier onset of disease and worse severity. Race/ethnicity is likely a 
stronger confounder for AMD than SDB as strong associations with AMD and 
participants of European ancestry have been reported (W. Wong et al., 2014). Smoking is 
shown to be strongly associated with AMD and studies have shown an association with 
SDB (Varol et al., 2015). Based on the shared confounders listed above it was important 
to control for these variables in the analyses that I discuss in more detail in Chapter 3. 
Summary 
In summary, the current research is inconclusive on the association between SDB 
and AMD and SDB and AMD severity. One of the main limitations to date has been the 
lack of a population-based research study to investigate the association between the two 
63 
 
 
 
diseases. In addition, there is no study to date that uses masked grading of retinal 
photographs to determine AMD severity and analyze these findings in light of a sleep 
questionnaire with multiple sleep related variables. Therefore, this study includes a large 
sample from the NHANES 2005–2008 survey period that includes fundus photography 
determined AMD status using masked graders and a validated grading protocol and a 
sleep questionnaire to capture self-reported variables for SDB. I will detail the 
methodology and analyses in Chapter 3. 
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Chapter 3: Research Method 
Introduction 
The purpose of this quantitative cross-sectional study was to evaluate the 
association between SDB and AMD in noninstitutionalized U.S. adults from 2005-2008 
and to serve as proof of concept to promote future research on causality. In Chapter 3, I 
present the study design and describe the study population, criteria for sample selection, 
definition of variables, data collection methodology, and instrumentation and materials. I 
also cover the NHANES 2005–2008 dataset and data analysis, the ethical protection of 
participants; and the Institutional Review Board () review and approval.  
Research Design and Rationale 
To address the research questions related to the purpose of this research, I 
investigated whether respondents with SDB (independent variable) had an increased 
prevalence of AMD (dependent variable) using nationally representative data, both with 
and without controlling for confounders.  Cross-sectional study designs have been 
commonly used to study associations between dependent and independent variables using 
population-based surveys such as NHANES (Creswell, 2014). There were no time or 
resource constraints for this study. 
Research Hypotheses  
The research questions and associated hypotheses that will guide this study are as 
follows:  
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Research Question 1: Is there an association between self-reported SDB and 
fundus photography identified AMD among adults 40 years and older who participated in 
the 2005–2008 NHANES survey before and after controlling for age, smoking, and BMI? 
H01: There is no association between self-reported SDB and fundus photography 
identified AMD among adults 40 years and older who participated in the NHANES 2005 
to 2008 survey before and after controlling for age, smoking, and BMI. 
H11: There is an association between self-reported SDB and fundus photography 
identified AMD among adult 40 years and older who participated in the NHANES 2005 
to 2008 survey before and after controlling for age, smoking, and BMI. 
Research Question 2: Is there an association between self-reported SDB and 
fundus photography identified neovascular AMD among adults 40 years and older who 
participated in the 2005–2008 NHANES survey before and after controlling for age, 
smoking, and BMI? 
H02: There is no association between self-reported SDB and fundus photography 
identified neovascular AMD among adults 40 years and older who participated in the 
NHANES 2005 to 2008 survey before and after controlling for age, smoking, and BMI. 
H12: There is an association between self-reported SDB and fundus photography 
identified neovascular AMD among adult 40 years and older who participated in the 
NHANES 2005 to 2008 survey before and after controlling for age, smoking, and BMI. 
Research Question 3: Is there an association between self-reported SDB and 
fundus photography identified geographic atrophy among adults 40 years and older who 
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participated in the 2005–2008 NHANES survey before and after controlling for age, 
smoking, and BMI? 
H03: There is no association between self-reported SDB and fundus photography 
identified geographic atrophy among adults 40 years and older who participated in the 
NHANES 2005 to 2008 survey before and after controlling for age, smoking, and BMI. 
H13: There is an association between self-reported SDB and fundus photography 
identified geographic atrophy among adult 40 years and older who participated in the 
NHANES 2005 to 2008 survey before and after controlling for age, smoking, and BMI. 
Methodology 
Population 
This study comprises adults 40 years and older that participated in the NHANES 
survey during the sampling timeframes of 2005-2006 and 2007-2008. The NHANES 
survey period of 2005–2008 is unique in that these two sampling frames include digital 
fundus photographs captured at a mobile examination center (MEC). Participants 
included in this study provided responses to the Sleep Disordered Questionnaire (SLQ) 
and had digital fundus photographs acquired as a part of NHANES. The population is 
comprised of noninstitutionalized individuals from the 50 states and the District of 
Columbia. The NHANES dataset does not include active duty military members by 
design (Zipf et al., 2013). 
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Sampling and Sampling Procedures  
The NHANES survey uses a multistage probability sampling design to select a 
sample representative of the civilian noninstitutionalized household population of the 
United States (Zipf et al., 2013). Sample selection, collection, and cleaning procedures 
for NHANES has been previously published (Zipf et al., 2013).  
An a priori power analysis was conducted to determine an adequate sample size 
using G*Power 3.1 (Faul, Erdfelder, Buchner, & Lang, 2009). Assumptions in 
determining minimum sample size included a two-tailed alpha of 0.05 and a power of 
90% to detect a weak association indicated by an OR of 1.2 (Monson, 1990). Monson 
(1990) indicates that an OR below 1.2 indicates no association. Therefore an OR of 1.2 
was used to estimate the minimum sample size needed; which was 1984 participants. 
According to Klein et al. (2011), 5553 participants that were ≥40 years of age in the 
2005–2008 NHANES dataset had at least 1 eye that could be evaluated for AMD. As 
nAMD and geographic atrophy (late AMD) are only present in a small portion of the 
population, the entire sample of participants that were ≥40 years of age, had at least 1 eye 
that could be evaluated for AMD, and completed the sleep disorder questionnaire will be 
included in the analyses. 
Procedures for Recruitment, Participation, and Data Collection 
The NHANES Survey is a national survey conducted by the National Center for 
Health Statistics and consists of a representative sample of the noninstitutionalized and 
civilian population of the United States. The first National Health Examination Survey 
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(NHES-1) was performed in 1959 (Zipf et al., 2013). During the years 1959-1970 the 
survey was performed periodically. As of 1999, the data has been continuously collected 
during concurrent sampling timeframes. The goals of this continuous survey is to provide 
prevalence data on selected diseases and risk factors for the U.S. population, to monitor 
trends in selected diseases, behaviors, and environmental exposures, to explore emerging 
public health needs, and to maintain a national probability sample of baseline information 
on health and nutritional status in the United States (Zipf et al., 2013). The NHANES is a 
unique survey as it not only contains participants’ self-reported health information from 
survey instruments, but also information from physical examinations and laboratory tests 
(Zipf et al., 2013). The participant interviews are conducted in the home, while the 
physical examinations are performed at a MEC. The combination of self-reported health 
information, physical examinations, and laboratory tests allows for analyses to be 
performed that would otherwise not be possible, or as accurate, with self-reported 
information alone (Zipf et al., 2013). Datasets from the NHANES survey are publically 
available and can be downloaded from the CDC website 
(http://www.cdc.gov/nchs/nhanes/).  
The MEC was used to collect retinal fundus images to assess the prevalence of 
vision loss and retinal diseases, such as AMD. Digital fundus photography was 
performed to obtain two 45° digital retinal images for each eye of NHANES participants 
involved in this ancillary study using the Canon CR6 non-mydriatic camera with a Canon 
10D camera back (6.3 megapixels per image) (CDC, 2005). Masked grading of digital 
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fundus photos eliminates recall bias that would otherwise be present from participant 
self-report, although this does not completely rule out the potential for misclassification 
bias that will be discussed further in this chapter. As this study investigated AMD as an 
ordinal variable, the grading of fundus photos will allow for the diagnosis of early signs 
of AMD that often do not cause visual disturbance in the patient and may not be 
communicated in survey findings alone. 
Operationalization of Variables 
The dependent variables for this study depend upon the research questions asked 
and included AMD status (categorical-none, early, and late AMD), nAMD, and 
geographic atrophy as defined by masked fundus photo grading. The independent 
variables included demographic variables (age, gender, race, BMI), diabetes status, 
smoking status (past or current smoker) and SDB variables (sleep apnea, sleep apnea 
symptoms of snoring and snorting/stop breathing, insomnia, short sleep duration, and any 
sleep disorder diagnosed by a physician or other health professional).  
Dependent variables (AMD, geographic atrophy, and choroidal 
neovascularization). The following AMD Variables are defined from masked grading of 
fundus photos as specified in the NHANES Digital Grading protocol and illustrated in 
Table 2 (CDC, 2005). Definitions for No AMD, Early AMD, and Late AMD are defined 
in the NHANES Digital Grading Protocol and this approach has been used in other 
NHANES research (Klein et al., 2011). No AMD is defined as gradable images without 
evidence of lesions associated with AMD. Early AMD was defined by the presence of 
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either soft indistinct drusen or the presence of retinal pigment epithelial depigmentation 
or increased retinal pigment, together with any type of drusen, or by the presence of soft 
drusen with an area of 500 μm or larger in absence of signs of late AMD. Late AMD was 
defined by the presence of any of the following: geographic atrophy or retinal pigment 
epithelial layer detachment, subretinal hemorrhage or visible subretinal new vessels, 
subretinal fibrous scar or laser treatment scar, or self-reported history of photodynamic or 
anti–vascular endothelial growth factor treatment for exudative AMD. I present these 
definitions in Table 2. 
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Table 2 
AMD Variables: NHANES 2005-2008 
Data 
variable 
Variable 
category 
Definition Variable 
recode 
OPDUARM No AMD Gradable images with no evidence of 
lesions associated with AMD. 
0 
 Early 
AMD 
Defined as either soft drusen present 
with a grid area of greater than a 500μm 
circle and a pigmentary abnormality 
present (increased pigment or 
depigmentation in the grid) or soft 
drusen present in the center circle and a 
pigmentary abnormality is present 
(increased pigment or depigmentation in 
the grid). No evidence of late AMD as 
defined below will be present. 
1 
 Late 
AMD 
Defined as the presence of any late 
lesions, such as GA, PED/RD 
detachments, subretinal hemorrhage, 
subretinal fibrous scar, subretinal new 
vessels, or laser treatment and/or 
/photodynamic therapy for AMD. 
2 
OPDUGA  Geographic Atrophy Absent = 0 
Present = 1 
OPDUEXU  Exudative AMD Absent = 0 
Present = 1 
 
Independent variables (SDB variables). SDB variables were based on 
participant self-report and came from the NHANES 2005–2008 sleep disorders 
questionnaire (SLQ). Previously published NHANES research has used this dataset and 
categorized the SDB variables in a similar fashion to what was done for this study (Chen 
et al., 2014; Seicean, Neuhauser, Strohl, & Redline, 2011). SDB variables were placed in 
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the following high-level categories: sleep apnea, SDB symptoms, insomnia, and insomnia 
symptoms. Sleep apnea was defined based on answering in the affirmative to following 
question: “Have you ever been told by a doctor or other health professional that you have 
a sleep disorder: sleep apnea?”  SDB symptoms were captured from questions on 
duration of sleep, habitual snoring, and snorting/stop breathing. Sleep duration was 
dichotomized to ≥6 hours vs. <6 hours. Habitual snoring was asked using the question: 
(1) “In the past 12 months, how often did you snore while you were sleeping?”. 
Snorting/Stop Breathing was collected using the question: “In the past 12 months, how 
often did you snort, gasp, or stop breathing while you were asleep?”. Participants who 
responded with “frequently (five or more nights per week)” were considered as having 
“habitual snoring” and “snorting/stop breathing,” respectively. Those participants that 
responded with “never,” “rarely (1-2 nights/week),” or “occasionally (3-4 nights/week)” 
were considered as having no snoring or snorting/stop breathing, respectively. Insomnia 
was defined based on answering yes to the following: “Have you ever been told by a 
doctor or other health professional that you have a sleep disorder (Insomnia)?” Insomnia 
symptoms were based on the answers to the following questions: “Do you have trouble 
falling asleep” (sleep latency) and “Do you wake up during the night and had trouble 
getting back to sleep” (nocturnal awakenings). A response to each insomnia symptom 
question was categorized as follows: negligible (2-4 times per month or less), mild to 
moderate (5-15 times per month), and severe (>15 times/month). These variables are 
presented in Table 3. 
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Table 3 
SDB Variables: NHANES 2005-2008 
Data set code Question Response(s) Study code 
Sleep Apnea Sleep Apnea 
SLQ.060 Have you ever been 
told by a doctor or 
other health 
professional that 
you have a sleep 
disorder? 
Yes  
SLQ.070 AND 
What was the sleep 
disorder? 
AND Sleep Apnea  
Sleep Disturbed Breathing Symptoms  
SLQ.010 
 
 
 
How much sleep do 
you usually get at 
night on weekdays 
or workdays? 
≥6 hours 
<6 hours 
Sleep 
Duration 
SLQ.030 In the past 12 
months, how often 
did you snore while 
you were sleeping? 
Habitual Snoring 
(Frequently, ≥5 nights/week) 
No Smoking (Never; Rarely, 
1-2 nights/week; 
Occasionally, 3-4 
nights/week) 
Snoring 
SLQ.040 In the past 12 
months, how often 
did you snort, gasp, 
or stop breathing 
while you were 
asleep? 
Snorting/Stop Breathing 
(Frequently, ≥5 nights/week) 
No Snorting/Stop Breathing 
(Never; Rarely, 1-2 
nights/week; Occasionally, 3-
4 nights/week) 
Snort/Stop 
Breathing 
SLQ.120 In the past month, 
how often did you 
feel excessively or 
overly sleepy during 
the day? 
Severe (Almost always, 16-
30 times a month) 
Mild to Moderate (Often, 5-
15 times a month) 
Negligible (Sometimes, 2-4 
times a month; Rarely, 1 
times a month; Never) 
Hypersomnol
ence 
Insomnia Diagnosed 
Insomnia 
  Continued  
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Data set code Question Response(s) Study code 
SLQ.060 Have you ever been 
told by a doctor or 
other health 
professional that 
you have a sleep 
disorder? 
Yes  
SLQ.070 AND What was the 
disorder? 
AND Insomnia  
Insomnia Symptoms 
SLQ.080 In the past month, 
how often did you 
have trouble falling 
asleep? 
Severe (Almost always, 16-
30 times a month) 
Mild to Moderate (Often, 5-
15 times a month) 
Negligible (Sometimes, 2-4 
times a month; Rarely, 1 
times a month; Never) 
Sleep 
Latency 
SLQ.080 In the past month, 
how often do you 
wake up during the 
night and have 
trouble getting back 
to sleep? 
Severe (Almost always, 16-
30 times a month) 
Mild to Moderate (Often, 5-
15 times a month) 
Negligible (Sometimes, 2-4 
times a month; Rarely, 1 
times a month; Never) 
Nocturnal 
Awakenings 
 
Sociodemographic and lifestyle characteristics. I present individual 
demographic data based on participant self-report in Table 4. These include age, gender, 
and race. 
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Table 4 
Demographic Variables: NHANES 2005-2008 
Variable name Description Level of 
measurement 
Study 
code 
Variable recode 
RIAGENDER Gender Binominal Gender Male = 1 
Female = 2 
RIDAGEYR Age in years of the 
participant at the time 
of screening. 
Nominal Age 40-59 
≥ 60 
RIDRETH1 Recode of reported 
race and ethnicity 
information. 
Nominal Ethnicity Mexican 
American = 1 
Other  
Hispanic = 2 
Non-Hispanic 
White = 3 
Black = 4 
Other race = 5 
BMXBMI Calculated BMI 
(kg/m2) 
Nominal BMI Normal =  
0-24.9 
Overweight= 
25.0-29.9 
Obese =  ≥30 
DIQ.010 Other than during 
pregnancy, have you 
ever been told by a 
doctor or other health 
professional that you 
have diabetes or 
sugar diabetes?  
Binominal  Diabetes Yes=1 
No=2 
 
Smoking history variables. Smoking status was based on participant self-report, 
and was divided into three categories, “current smoker”, “past smoker”, and nonsmoker. 
These variables are presented in Table 5. Current smokers were categorized as all 
individuals who responded positively to smoking at least 100 cigarettes in a lifetime and 
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smoking cigarettes every day or some days. Past smokers were categorized as those who 
had smoked at least 100 cigarettes and who replied that they no longer smoked cigarettes. 
A nonsmoker was categorized as any individual who had smoked fewer than 100 
cigarettes in their lifetime. 
Table 5 
Smoking Variables: NHANES 2005-2008 
Data set code Question Response Study code 
Current smoker   Current smoker 
SMQ.020 Have you smoked 
at least 100 
cigarettes in your 
entire life? 
Yes  
SMQ.040 AND Do you now 
smoke cigarettes? 
AND Every day 
OR Some days 
 
Past smoker   Past smoker 
SMQ.020 Have you smoked 
at least 100 
cigarettes in your 
entire life? 
Yes  
SMQ.040 AND Do you now 
smoke cigarettes? 
AND Not at all  
Nonsmoker   Nonsmoker 
SMQ.020 Have you smoked 
at least 100 
cigarettes in your 
entire life? 
No  
 
Data Analysis Plan 
Analyses was performed using SPSS software (IBM Corp. Released 2013. IBM 
SPSS Statistics for Mac, Version 23.0. Armonk, NY: IBM Corp). Datasets from the 
2005-2006 and 2007-2008 survey periods were merged to produce an analysis dataset. 
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Variables were recoded, as needed, based on the specifications previously described in 
the section on operationalization of variables. 
The research questions and associated hypotheses that guided this study are as 
follows:  
Research Question 1: Is there an association between self-reported SDB and 
fundus photography identified AMD among adults 40 years and older who participated in 
the 2005–2008 NHANES survey before and after controlling for age, smoking, and BMI? 
H01: There is no association between self-reported SDB and fundus photography 
identified AMD among adults 40 years and older who participated in the NHANES 2005 
to 2008 survey before and after controlling for age, smoking, and BMI. 
H11: There is an association between self-reported SDB and fundus photography 
identified AMD among adult 40 years and older who participated in the NHANES 2005 
to 2008 survey before and after controlling for age, smoking, and BMI. 
Research Question 2: Is there an association between self-reported SDB and 
fundus photography identified neovascular AMD among adults 40 years and older who 
participated in the 2005–2008 NHANES survey before and after controlling for age, 
smoking, and BMI? 
H02: There is no association between self-reported SDB and fundus photography 
identified neovascular AMD among adults 40 years and older who participated in the 
NHANES 2005 to 2008 survey before and after controlling for age, smoking, and BMI. 
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H12: There is an association between self-reported SDB and fundus photography 
identified neovascular AMD among adult 40 years and older who participated in the 
NHANES 2005 to 2008 survey before and before and after controlling for age, smoking, 
and BMI. 
Research Question 3: Is there an association between self-reported SDB and 
fundus photography identified geographic atrophy among adults 40 years and older who 
participated in the 2005–2008 NHANES survey before and after controlling for age, 
smoking, and BMI? 
H03: There is no association between self-reported SDB and fundus photography 
identified geographic atrophy among adults 40 years and older who participated in the 
NHANES 2005 to 2008 survey before and after controlling for age, smoking, and BMI. 
H13: There is an association between self-reported SDB and fundus photography 
identified geographic atrophy among adult 40 years and older who participated in the 
NHANES 2005 to 2008 survey before and after controlling for age, smoking, and BMI. 
To answer these research questions, I first conducted a chi-square test for 
association to determine any differences in the distribution of AMD across 
sociodemographic, lifestyle, and sleep characteristics. Cumulative odds OLR with 
proportional odds (ordinal dependent variable= no AMD, early AMD, late AMD) 
regression and binomial logistic regression modeling (dependent variable=no choroidal 
neovascularization, choroidal neovascularization present; no geographic atrophy, 
geographic atrophy present) were fit to understand the association between AMD and 
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sleep parameters with adjustment for sociodemographic and lifestyle factors. Survey 
specific sampling design variables and sampling weights were incorporated in the 
analyses to account for the complex multistage sampling design of NHANES. The two 
main objectives of this OLR were as follows: (a) to determine which of the independent 
variables (if any) have a statistically significant effect on AMD; and (b) determine how 
well the OLR model predicts AMD. An OLR analysis was performed that only included 
SDB variables (sleep apnea, sleep apnea symptoms of snoring and snorting/stop 
breathing, insomnia, short sleep duration, and any sleep disorder diagnosed by a 
physician or other health professional). The second model was adjusted for demographic 
variables identified as confounders (age, BMI) and smoking status (past or current 
smoker) and tested with a multivariable regression analysis. Binomial logistic regression 
models were created to test the association with nAMD and geographic atrophy with 
SDB, respectively. These binomial logistic regression models were adjusted for the same 
independent variables as with the cumulative odds OLR with proportional odds analyses 
listed above. In accordance with the number of analyses conducted, adjustment of the 
significance level by the method of Sequential Sidak was incorporated. Data analyses 
were performed using SPSS software using the Cross Tabs, Complex Samples OLR, and 
Complex Samples Logistic Regression procedures (IBM Corp. Released 2013. IBM 
SPSS Statistics for Mac, Version 23.0. Armonk, NY: IBM Corp). ORs and 95% 
confidence intervals (95% CIs) were calculated for all models.  
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Threats to Validity 
The current study used data from the 2005–2008 NHANES sampling periods to 
evaluate the association between AMD and SDB. The NHANES survey captures data 
from a single point in time (cross-sectional) and therefore provided little to no basis for 
assumptions about causality. Due to this limitation of the design, the study was only 
interpreted in terms of illustrating an association between AMD and SDB. 
NHANES participants are only sampled from the United States, so 
generalizability to other populations may not be accurate (external validity). In addition, 
the NHANES survey does not include individuals who were institutionalized (e.g., 
nursing home residents, incarcerated individuals, long term care facility residents) at the 
time of the survey. Based on this study’s requirements for interpreted retinal fundus 
photographs, I was unable to include a substantial number of participants who did not 
have photographs taken, or for whom the photos taken were considered ungradable. 
Participants that had no ability to perceive light, severe visual impairment in both eyes, or 
an infection in at least one eye were excluded from fundus photography (CDC, 2005). 
Lastly, due to the sampling timeframes and the limited years available in this analysis, 
certain ethnic subgroups may be underestimated. NHANES provides ethnicity as a 
recoded data variable with the categories of Mexican American, Other Hispanic, Non-
Hispanic White, Non-Hispanic Black, and Other. As there is no granularity with regards 
to the ethnicity/race in the Other categories, it was not possible to assess the association 
with populations other than the recoded variable provided by NHANES. This may have 
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had little impact on the analyses as AMD has a relatively high prevalence in the non-
Hispanic White population while it is relatively rare in Blacks and Latinos (Klein et al., 
2011). The entire available sample that met my inclusion criteria was analyzed regardless 
of ethnicity. 
Ethical Considerations 
As this study used secondary data from persons who participated in the NHANES 
survey, measures were employed to ensure participant protection prior to and during data 
collection (Zipf et al., 2013). This study used de-identified data and there was and will be 
no effort to contact those NHANES participants who are included in the study. In this 
study, I used all available data that met the pre-specified inclusion criteria of ≥40 years of 
age, had at least one eye that could be evaluated for AMD, and completed the sleep 
disorder questionnaire. 
The NHANES survey data is publicly available; it has been previously reviewed 
by the NCHS Research Ethics Review Board [ERB] (CDC, 2016a). All subjects were 
administered and provided informed consent prior to participation in NHANES. The 
Walden University Institutional Review Board (IRB) provided a review and was 
responsible for oversight for the analyses of this secondary data set (IRB approval 
number 11-15-16-0260551). The anonymized data sets were downloaded from the 
publically available NHANES website and stored on my local workstation with 
appropriate back-up software in place. I will maintain the data for the latter of 3 years 
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after the publication of this dissertation and/or the publication of the results in a peer-
reviewed journal.  
Summary 
In Chapter 3, I provided the methodology to perform this quantitative, cross-
sectional study based on a life course approach to chronic disease. The primary objective 
of this project was to identify if there is an association with AMD and SDB for 
noninstitutionalized U.S. adults over the age of 40 from the NHANES sampling periods 
2005-2008. The association was investigated in the context of demographic variables, 
smoking variables, and SDB variables. The results of the current study may provide 
patients, caregivers, and healthcare providers essential information for the prevention and 
treatment of AMD.  
Results, including the demographics of the sample and the findings gleaned from 
my use of ordinal and binomial logistic regression are presented in Chapter 4.
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Chapter 4: Results 
Introduction 
The purpose of this quantitative cross-sectional study was to evaluate the 
association between SDB and AMD in noninstitutionalized U.S. adults from 2005-2008 
and to serve as proof of concept to promote future research on causality. To achieve this 
purpose, I tested the hypotheses using secondary data from the 2005–2008 NHANES 
survey sampling frames. A multistage probability sampling design was used by 
NHANES to select a sample representative of the civilian, noninstitutionalized household 
population of the United States that has been previously published in the peer reviewed 
literature (Zipf et al., 2013). 
In Chapter 4, I present the demographics of the study sample, bivariate 
relationships between the dependent and independent variables, an evaluation of potential 
confounders to that relationship, and the odds ratios determined through my use of 
ordinal and binary logistic regression. The first hypothesis, testing the association 
between SDB and AMD was assessed by performing a preliminary chi-square test for 
association to determine any differences in the distribution of AMD across 
sociodemographic, lifestyle, and sleep characteristics. Each SDB variable was then 
incorporated into a complex samples OLR model with and without adjustment for 
covariates. I used a multivariate model to incorporate the statistically significant SDB and 
covariate variables to estimate the strength, significance, and direction of the primary 
relationships. The second and third hypothesis testing the association between SDB and 
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choroidal neovascularization and SDB and geographic atrophy, respectively, had to be 
collapsed due to the rare prevalence of these two subpopulations in the study sample. 
This resulted in a single research question addressing the association of SDB with late 
AMD (choroidal neovascularization and geographic atrophy). Therefore, RQ 2 is as 
follows: Is there an association between self-reported SDB and fundus photography 
identified late AMD among adults 40 years and older who participated in the 2005–2008 
NHANES survey before and after controlling for age, smoking, and BMI?  This research 
question was analyzed using the complex samples binary logistic regression model and 
included the covariates age, BMI, and smoking status identified in in the assessment of 
the first research question.  
Data Collection  
The source of secondary data for this study was the NHANES 2005–2008 survey. 
The NHANES is an appropriate data collection tool as it utilizes sampling techniques to 
survey a representative of the civilian noninstitutionalized household population of the 
United States during each sampling timeframe (Zipf et al., 2013). The sampling design 
for the 2005–2008 survey years has been previously described in detail in the peer-
reviewed literature (National Center for Health Statistics [U.S.], 2012, 2013). In 
summary, a multistage sample design was used in NHANES 2005-2008. The first stage 
of the sample design consisted of selecting the primary sampling units (PSU) from all 
U.S. counties, using the 2000 U.S. Census Bureau data. The second sampling stage 
divided each PSU into blocks or groups of blocks containing household clusters. 
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NHANES oversampled specific populations that could be underrepresented with basic 
survey methodology and are of particular public health interest. In the 2005-2006 
sampling timeframe, Mexican-American, Black, low-income White, and other persons (at 
or below 130% of federal poverty level); adolescents aged 12–19; and non-Hispanic 
White and other adults aged 70 and over were oversampled (National Center for Health 
Statistics [U.S.], 2013). In the 2007-2008 sampling timeframe Hispanic, non-Hispanic 
Black, low-income non-Hispanic White, and other persons (at or below 130% of federal 
poverty level); and non-Hispanic White and other adults aged 80 and over were 
oversampled (National Center for Health Statistics [U.S.], 2013). 
Results 
Descriptive Characteristics 
The NHANES survey is a national survey that collects data from approximately 
5,000 participants within the U.S. population each year such that the data will enable 
extrapolation to the U.S. population (CDC, 2011). A total of 10,348 participants were 
included in the 2005-2006 NHANES survey; 9,950 and 398 participants were 
administered interviews and examinations or interviews alone, respectively (CDC, 
2009a). Data from these participants was collected from November 1, 2005 to October 
31, 2006. A total of 10,149 participants were included in the 2007-2008 NHANES 
survey; 9,762 and 387 participants were administered interviews and examinations or 
interviews alone, respectively (CDC, 2009b). Data from these participants was collected 
from November 1, 2007 to October 31, 2008. The sample for these analyses was limited 
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to those survey participants that had data for both the dependent (AMD) and independent 
variables (SDB). Only those survey participants that were 40 years and older were 
eligible to have ophthalmology examinations, therefore by definition the sample only 
included individuals above this age cut-off. The available cases for analyses are detailed 
in Figure 4. 
 
Figure 4. Participant flowchart detailing the number of cases available for 
analysis. 
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In Table 6, I report the frequencies and percentages of the sociodemographic 
characteristics of the unweighted NHANES sample (n = 20,497), the unweighted study 
sample (n=5,604) and the weighted study sample (n = 227,456,895). During the survey 
periods 2005-2006 and 2007-2008, 20,497 participants were interviewed and/or 
examined in NHANES. Only those participants ≥ 40 had the option of participating in the 
ophthalmology-retinal imaging examination and therefore the available sample size for 
this study was 5,604 participants (Figure 4). As AMD presents rarely before the age of 40 
years, this inherent age cut-off due to the NHANES examination methodology did not 
adversely alter the study sample. The weighted sample demographics are provided in 
Table 6 to allow estimates of the parameters that would have been obtained were the 
entire U.S. population surveyed (CDC, 2009b).  
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Table 6 
Sociodemographic characteristics of NHANES Sample, Study Sample, and Weighted 
Study Sample 
 
Characteristic NHANES 
Sample1,2 
Study Sample1 Weighted Study 
Sample 
 N=7,081  
n (%) 
N=5604  
n (%) 
N=227,456,895 
(%) 
Age    
40-59 3357 (47.4) 2829 (50.5) 64.4 
≥ 60 3724 (52.6) 2775 (49.5) 35.6 
Gender    
Women 3575 (50.5) 2793 (49.8) 52.6 
Men 3506 (49.5) 2811 (50.2) 47.4 
Race/Ethnicity3    
Non-Hispanic 
White 
3688 (52.1) 3017 (53.8) 77.1 
Non-Hispanic 
Black 
1514 (21.4) 1139 (20.3) 9.6 
Other Hispanic 518 (7.3) 864 (15.4) 7.6 
Mexican American 1103 (15.6) 40 (7.2) 4.7 
Other race 258 (3.6) 183 (3.3) NA2 
Smoking status4    
Nonsmoker 3433 (48.5) 2648 (47.3) 48.5 
Past smoker 2248 (31.8) 1812 (32.3) 30.9 
Current smoker 1391 (19.7) 1142 (20.4) 20.6 
Diabetes status    
No 5744 (81.2) 4643 (83.0) 87.4 
Yes 1329 (18.8) 954 (17.0) 12.6 
BMI    
Normal 1724 (26.3) 1410 (25.7) 27.5 
Overweight 2328 (35.5) 1973 (35.9) 35.3 
Obese 2505 (38.2) 2109 (38.4) 37.2 
1Unweighted 
2NHANES sample of those participants >40 years of age 
3Weighted estimates not provided for “other race” category that includes multiple 
ethnic groups. 
4Nonsmoker was defined as a respondent who had not smoked at least 100 
cigarettes in their life; a past smoker was defined as a respondent who had smoked at 
least 100 cigarettes in their life although do not now smoke cigarettes, current smoker 
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defined as survey respondents who have smoked at least 100 cigarettes in their life and 
now smoke cigarettes. 
 
The sample included slightly more men (51.2%) than women. The sample also 
include more Non-Hispanic Whites (51.2%) than the combined other races/ethnicities. 
Half of the sample responded that they were nonsmokers, while 17% reported having 
received a diagnosis of diabetes. Of note, a higher percentage of the sample was 
identified as obese rather than overweight or normal based on the CDC definitions using 
BMI. 
As I was unable to use the entire sample for NHANES 2005–2008 due to the need 
for the AMD grading, I used the chi-square Goodness of Fit test to compare my sample to 
the NHANES sample over the age of 40. The results of this analysis are presented in 
Table 7. 
Table 7 
Goodness of Fit Results from Comparison of NHANES and this Study’s Sample 
Characteristic Chi-square p value 
Age 0.64 0.42 
Gender 0.04 0.84 
Race/ethnicity 17.01 0.002 
Diabetes 0.26 0.61 
BMI 0.21 0.90 
 
These results suggest that the sample I used was not significantly different from 
the original sample in all sociodemographic variables except race/ethnicity. As the 
weighting is based on the entire NHANES sample, I had to use caution in my 
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interpretation of race/ethnicity. The impact of this is minimal in later analyses as only 
age, smoking status, and BMI were included in my models as potential confounders. 
Table 8 summarizes the SDB variables for the unweighted NHANES sample 
(n=7,081), the unweighted study sample (n=5,604) and the weighted study sample 
(n=227,456,895).  
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Table 8 
SDB characteristics of NHANES Sample, Study Sample, and Weighted Study Sample 
Characteristic NHANES 
Sample1,2 
Study Sample1 Weighted Study 
Sample 
 N=7,081  
n (%) 
N=5604  
n (%) 
N=227,456,895 
(%) 
Any diagnosed sleep disorder3   
No 6431 (90.8) 5088 (90.8) 95.3 
Yes 650 (9.2) 516 (9.2) 4.7 
Diagnosed sleep apnea   
No 6656 (94.7) 5260 (94.5) 97.4 
Yes 373 (5.3) 305 (5.5) 2.6 
Snoring    
No 3869 (62.6) 3048 (61.7) 70.0 
Habitual 2315 (37.4) 1891 (38.3) 30.0 
Snorting/stop breathing   
No 5913 (93.1) 4705 (93.2) 97.1 
Yes 435 (6.9) 343 (6.8) 2.9 
Diagnosed insomnia   
No 6905 (98.2) 5468 (98.3) 99.6 
Yes 124 (1.8) 97 (1.7) 0.4 
Prolonged sleep latency4   
Negligible 5825 (82.3) 4624 (82.5) 83.1 
Mild to moderate 658 (9.3) 512 (9.1) 8.0 
Severe 591 (8.3) 466 (8.3) 8.9 
Nocturnal awakenings4   
Negligible 5513 (78.0) 4351 (77.7) 75.9 
Mild to moderate 918 (13.0) 753 (13.4) 15.0 
Severe 640 (9.1) 499 (8.9) 9.1 
Hypersomnolence4    
Negligible 5870 (83.1) 4675 (83.5) 82.3 
Mild to moderate 754(10.7) 599 (10.7) 11.1 
Severe 442 (6.3) 324 (5.8) 6.6 
Sleep duration    
≥6 hours 5916 (83.5) 4706 (84.0) 89.4 
< 6 hours 1165 (16.5) 898 (16.0) 10.6 
1Unweighted 
2NHANES sample of those participants >40 years of age 
3Sleep Disorders categorized as sleep apnea, insomnia, restless leg syndrome, other 
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4Prolonged Sleep Latency, Nocturnal Awakenings, and Hypersomnolence defined as 
Severe (Almost Always 16-30 times a month); Mild to Moderate (Often 5-15 times a 
month); Negligible (Sometimes 2-4 times a month; Rarely 1 time a month; Never). 
 
Nine percent of participants self-reported that they had been diagnosed with a 
sleep disorder; 6% and 2% were diagnosed with sleep apnea and insomnia, respectively. 
In contrast 38% of participants self-reported snoring more than 5 or more nights per week 
and 18% reported receiving less than 6 hours of sleep on average. 
There were more participants providing responses to the sleep questionnaire than 
participated in the mobile examination center data collection of retinal fundus photos. 
Therefore, the sample size of the study sample is limited by the availability of data from 
the masked grading of fundus photos. Figure 5 illustrates the AMD demographics (worse 
eye) based on grading performed using the modified Wisconsin Age-Related 
Maculopathy Grading System. Overall the prevalence of any AMD in the study sample 
was 7.9% with 6.9% categorized as early AMD and 1.0% as late AMD. Of the 
participants with late AMD, 0.6% and 0.4% were graded as having geographic atrophy 
and choroidal neovascularization, respectively. 
 
93 
 
 
 
  
Figure 5. AMD demographics (worse eye) in 5604 participants in the NHANES 
2005–2008 survey. 
Research Question 1: Chi-Square Analyses 
In the first research question, I asked whether there is an association between self-
reported SDB and fundus photography identified AMD among adults 40 years and older 
who participated in the 2005–2008 NHANES survey. A preliminary chi-square test for 
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association was conducted between the presence or absence of AMD and 
sociodemographic characteristics of the study sample. The results of these analyses are 
presented in Table 9. 
Table 9 
Chi-square Test of Association between AMD and Sociodemographic Characteristics 
Characteristic No AMD Any AMD p Value1 
 n=5163  
n (%) 
n=441  
n (%) 
 
Age   <.001 
40-59 2753 (53.3) 76 (17.2)  
≥ 60 2410 (46.7) 365 (82.8)  
Gender   .439 
Women 2581 (50.0) 212 (48.1)  
Men 2582 (50.0) 229 (51.9)  
Race/Ethnicity   <.001 
Non-Hispanic 
White 
2703 (52.4) 314 (71.2)  
Non-Hispanic 
Black 
1103 (21.4) 36 (8.2)  
Other Hispanic 376 (15.7) 25 (12.0)  
Mexican American 811(3.3) 53 (2.9)  
Other race 170 (7.3) 13 (5.7)  
Smoking status2   <.001 
Nonsmoker 2451 (47.5) 197 (44.7)  
Past smoker 1634 (31.7) 178 (40.3)  
Current smoker 1076 (20.8) 66 (15.0)  
Diabetes status   .791 
No 4280 (83.0) 363 (82.5)  
Yes 877 (17.0) 77 (17.5)  
BMI3   .021 
Normal 1290 (25.5) 120 (27.8)  
Overweight 1800 (35.6) 173 (40.0)  
Obese 1970 (38.9) 139 (32.2)  
1 χ2 test for association was conducted, p < .05 
2Nonsmoker defined as survey respondents that have not smoked at least 100 cigarettes in 
their life, past smoker defined as survey respondents that have smoked at least 100 
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cigarettes in their life although do not now smoke cigarettes, current smoker defined as 
survey respondents that have smoked at least 100 cigarettes in their life although and now 
smoke cigarettes. 
3BMI categories as defined by CDC 
 
All expected cell frequencies were greater than five. There was a statistically 
significant association between AMD and age, χ2 (df = 1) = 211.68, p < .001; 
race/Ethnicity, χ2 (df = 4) = 66.86, p < .001; smoking status, χ2 (df =2) = 17.09, p < 
.001; and BMI, χ2 (df =2) = 7.76, p = .021. There was no association between AMD and 
gender or diabetes status. Thus, those variables were not included as potential 
confounders in the remaining analyses. 
A chi-square test for association was conducted between AMD and SDB 
characteristics of the study sample. The results are presented in Table 10. 
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Table 10 
Chi-square Test of Association between AMD and SDB Characteristics 
Characteristic No AMD Any AMD p Value1 
 n=5163  
n (%) 
n=441  
n (%) 
 
Any diagnosed sleep disorder  .004 
No 4671 (90.5) 417 (94.6)  
Yes 492 (9.5) 24 (5.4)  
Diagnosed sleep apnea  .015 
No 4833 (94.3) 427 (97.0)  
Yes 292 (5.7) 13 (3.0)  
Snoring   .144 
No 2804 (61.4) 244 (65.2)  
Habitual 1761 (38.6) 130 (34.8)  
Snorting/stop breathing  .022 
No 4324 (93.0) 382 (96.0)  
Yes 327 (7.0) 16 (4.0)  
Diagnosed insomnia  .311 
No 5033 (98.2) 435 (98.9)  
Yes 92 (1.8) 5 (1.1)  
Prolonged sleep latency2  .172 
Negligible 4254 (82.4) 370 (83.9)  
Mild to moderate 482 (9.3) 30 (6.8)  
Severe 425 (8.2) 41 (9.3)  
Nocturnal awakenings2  .503 
Negligible 4014 (77.8) 337 (76.4)  
Mild to moderate 695 (13.5) 58 (13.2)  
Severe 453 (8.8) 46 (10.4)  
Hypersomnolence2   .230 
Negligible 4318 (83.7) 357 (81.1)  
Mild to moderate 549 (10.6) 50 (11.4)  
Severe 291 (5.6) 33 (7.5)  
Sleep duration   .087 
≥6 hours 4323 (83.7) 383 (86.8)  
< 6 hours 840 (16.3) 58 (13.2)  
1 χ2 test for association was conducted, p <.05 
2Prolonged Sleep Latency, Nocturnal Awakenings, and Hypersomnolence defined as 
Severe (Almost Always 16-30 times a month); Mild to Moderate (Often 5-15 times a 
month); Negligible (Sometimes 2-4 times a month; Rarely 1 time a month; Never) 
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All expected cell frequencies were greater than five. There was a statistically 
significant association between AMD and self-reported diagnosis of any sleep disorder, 
χ2 (1) = 8.119, p=.004; self-reported diagnosis of sleep apnea, χ2 (1) = 5.89, p=.015; and 
self-reported snorting/gasping/stop breathing χ2 (1) = 5.25, p=.022. There were no 
associations between AMD and snoring, insomnia, prolonged sleep latency, nocturnal 
awakenings, hypersomnolence, or sleep duration.  
Research Question 1: Complex Samples OLR. To address the hypotheses 
associated with these research questions, I included the variable for the 3-level AMD 
severity (dependent variable) and the nine SDB (independent variables) included 
separately in the models and then adjusted for covariates. As NHANES uses a complex, 
multistage, probability sampling design (including oversampling) to select participants, I 
elected to use the Complex Samples OLR procedure in SPSS for analyses. Weighting 
variables were applied to assure that the output is representative of the U.S. civilian 
noninstitutionalized 2000 Census population (CDC, 2009a, 2009b). The dependent 
variable was the categorical AMD severity scale (no AMD, early AMD, and late AMD) 
determined from the grading of fundus photos. Independent variables were tested for 
multicollinearity in SPSS using the linear procedure. All tolerance values were greater 
than 0.1 (the lowest value was 0.639) and Variance Inflation Factor (VIF) values were 
less than 10 (the highest value was 1.565), indicating that the assumption related to 
multicollinearity was met. The results of the OLR models for the association of AMD 
and SDB characteristics are presented in Table 11.  
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Table 11 
Ordinal Logistic Regression Models: Association of SDB and AMD 
Outcome variable Unadjusted p Value1 Adjusted2 p Value1 
 OR (95% CI)  OR (95% CI)   
Any diagnosed 
sleep disorder 
2.2 (1.2-3.9) .009 2.0 (1.2-3.6) .015 
Diagnosed sleep 
apnea 
2.6 (1.4-5.1)  .005 2.6 (1.3-4.9) .006 
Snoring  1.5 (1.1-2.0) .018 1.3 (1.0-1.8) .070 
Snorting/stop 
breathing  
2.8 (1.3-6.0) .010 2.4 (1.1-5.1) .024 
Diagnosed 
insomnia 
3.1 (1.1-9.0) .029 2.3 (0.9-6.4) .095 
Prolonged sleep latency    
Mild to moderate 
vs. Negligible 
1.3 (0.8-1.9) .454 1.1 (0.7-1.7) .430 
Severe vs. 
Negligible 
0.9 (0.5-1.5) .454 0.8 (0.5-1.3) .430 
Nocturnal awakenings    
Mild to moderate 
vs. Negligible 
1.0 (0.6-1.5) .186 0.9 (0.6-1.4) .693 
Severe vs. 
Negligible 
0.9 (0.6-1.4) .186 0.8 (0.6-1.1) .693 
Hypersomnolence     
Mild to moderate 
vs. Negligible 
1.0 (0.6-1.7) .752 1.0 (0.5-1.6) .444 
Severe vs. 
Negligible 
0.8 (0.4-1.5) .752 0.7 (0.3-1.3) .444 
Sleep duration 1.3 (0.8-2.1) .232 1.2 (0.8-1.8) .493 
1 Complex Samples Ordinal Logistic Regression was conducted, p < .05 
2The SDB variables were adjusted for age, BMI, and smoking status. 
 
Models are presented unadjusted as well as adjusted for age, BMI, and smoking 
status. Though race/ethnicity was significantly associated with AMD in the chi-square 
analysis as presented in Table 9, this association was negated with the addition of the 
SDB variables; thus, this variable was not included as a potential confounder in the 
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multivariate analysis. Participants with AMD were associated with self-reported 
diagnosis of any sleep disorder (OR, 2.2; 95% CI, 1.2-3.9), self-reported diagnosis of 
sleep apnea (OR, 2.6; 95% CI, 1.4-5.1), and self-reported snorting/stop breathing (OR, 
2.8; 95% CI, 1.3-6.0). Association between AMD and snoring (OR, 1.5; 95% CI, 1.1-2.0) 
and between AMD and Insomnia (OR, 3.1; 95% CI, 1.1-9.0) were significant in 
unadjusted models, although once I controlled for the covariates, did not exhibit a 
significant association. Prolonged sleep latency, nocturnal awakenings, 
hypersomnolence, and sleep duration were not associated with AMD. 
A multivariate model was built with independent variables and covariates that 
were statistically significant with a p value of < 0.1 based on any of the OLR analyses of 
the unadjusted/adjusted models illustrated in Table 11. Independent variables included in 
the model were diagnosed sleep apnea, snoring, snorting/stop breathing, and diagnosed 
insomnia. Although the p value for any diagnosed sleep disorder met the threshold for 
inclusion, this variable was inclusive of the variables for sleep apnea and insomnia (also 
included choices of restless leg syndrome and other) and did not present as having as 
strong of an association as diagnosed sleep apnea alone. Insomnia was statistically 
significant in the unadjusted model and was therefore included. Covariates that were 
included in the multivariate model were age, smoking, and BMI. The results of the 
multivariate model are presented in Table 12. 
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Table 12 
Multivariate Model for Association of SDB and AMD 
Outcome variable OR (95% CI)  p Value1 
Diagnosed sleep apnea 2.2 (1.1-4.5) .03 
Snoring  1.1 (0.8-1.5) .45 
Snorting/stop 
breathing  
2.4 (1.3-4.5) .007 
Diagnosed insomnia 1.8 (0.6-5.2) .30 
Age 5.3 (3.5-8.0) <.001 
Smoking 1.1 (0.8-1.3) .31 
BMI 0.9 (0.8-1.1) .28 
1 Based on complex samples ordinal logistic regression.  
In the multivariate model, I found significant associations between diagnosed 
sleep apnea, snorting/stop breathing, and age; and AMD. Thus, I was able to reject the 
null hypothesis associated with RQ 1. 
Cox & Snell R2, Nagelkerke R2, and McFadden R2 tests were performed for all 
models to compare the relative strength of each model. These are presented in Table 13.  
Table 13. 
Cox & Snell R2, Nagelkerke R2, and McFadden R2 Values, by Model 
Outcome Variable Cox & Snell R2 Nagelkerke R2 McFadden R2 
Any diagnosed sleep 
disorder 
.042 .101 .080 
Diagnosed Sleep Apnea .043 .103 .082 
Snoring .040 .099 .079 
Snorting/Gasping/Stop 
breathing 
.040 .098 .078 
Multivariate Model1 .045 .109 .087 
1 Reported for those variables exhibiting a statistically significant (p<.1) association with 
AMD severity in Complex Samples Ordinal Logistic Regression models (variables 
included in the equation were diagnosed sleep apnea, diagnosed insomnia, snoring, 
snorting/gasping/stop breathing, snoring, age, smoking, and BMI). 
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Whether I referenced the Cox & Snell R2, Nagelkerke R2, or McFadden R2 
methods the pseudo R2 for any diagnosed sleep disorder alone ranges from 4.2% to 
10.1%. The pseudo R2 based on the self-reported diagnosis of sleep apnea model ranges 
from 4.3% to 10.3%. The pseudo R2 based on the snoring model ranges from 4.0% to 
7.9%. The pseudo R2 based on the self-reported snorting/gasping model ranges from 
4.0% to 9.8%. The pseudo R2 based on the multivariate model ranges from 4.5% to 
10.9%. This suggests that the multivariate model is the strongest one, though none can be 
considered predictive. 
The assumption of proportional odds was tested in SPSS by performing separate 
binomial logistic regressions on cumulative dichotomous dependent variables. NHANES 
provides a collapse of Early AMD and Late AMD to form the Any AMD variable as well 
as the collapse of the No AMD and Early AMD to form the Late AMD variable. Table 14 
summarizes the odds ratios and 95% CI for each independent variable for the two logistic 
regression analyses. 
Table 14 
Proportional Odds Testing: Separate Binomial Logistic Regression Models 
Outcome variable No AMD vs. Any AMD 
OR (95% CI)1 
No Late AMD vs. Late AMD 
OR (95% CI)1 
Diagnosed sleep apnea 2.2 (1.1-4.5) NA2 
Snoring  1.1 (0.8-1.5) NA2 
Snorting/stop 
breathing  
2.4 (1.3-4.4) NA2 
Diagnosed insomnia 1.8 (0.7-5.0) NA2 
Smoking 1.0 (0.6-1.7) NA2 
Age 5.5 (3.8-7.9) NA2 
BMI 1.2 (0.9-1.6) NA2 
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1 Complex Samples Logistic Regression  
2 A quasi-complete separation was detected in the data; therefore the results should be 
interpreted with caution. 
 
The number of participants in the late AMD category was small and a complete 
separation occurred when performing the logistic regression. Therefore, the results should 
be interpreted with caution, as the assumption of proportional odds was not met. 
Research Question 2 and 3: Complex Samples Logistic Regression 
Research questions 2 and 3 were performed to investigate the association of SDB 
variables with choroidal neovascularization and geographic atrophy, respectively. Based 
on the complete separation that occurred when assessing proportional odds for RQ 1 and 
performing logistic regression using Late AMD as the dependent variable, I decided to 
collapse the choroidal neovascularization and geographic atrophy variables for analysis. 
Combining these variables modified RQ 2 and 3 into the following single research 
question:  
Research Question 2: Is there an association between self-reported SDB and 
fundus photography identified late AMD among adults 40 years and older who 
participated in the 2005–2008 NHANES survey after controlling for age, smoking, and 
BMI? 
H02: There is no association between self-reported SDB and fundus photography 
identified late AMD among adults 40 years and older who participated in the NHANES 
2005 to 2008 survey after controlling for age, smoking, and BMI. 
H12: There is an association between self-reported SDB and fundus photography 
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identified late AMD among adult 40 years and older who participated in the NHANES 
2005 to 2008 survey after controlling for age, smoking, and BMI. 
Late AMD was a variable provided in the NHANES dataset and therefore no 
recoding of variables was necessary. The variable for Late AMD (dependent variable) 
and the omnibus variable for Any Diagnosed Sleep Disorder (independent variable) were 
used to assure model saturation and to address the hypothesis associated with this 
question. The results of the Complex Samples Logistic Regression are presented in Table 
15.  
Table 15 
Multivariate Model of the Association of Late AMD and Any Diagnosed Sleep Disorder 
Outcome Variable OR (95% CI) p Value1 
Any Diagnosed Sleep 
Disorder 
0.8 (0.2-4.2) .74 
Age 130.8 (16.6-1030.8) <.001 
Smoking 0.9 (0.6-1.3) .66 
BMI 0.6 (0.4-1.0) .04 
1 Complex Samples Logistic Regression p < .05 
In this model, there was no association of late AMD to any diagnosed sleep 
disorder. Thus, I was unable to reject the null hypothesis. 
 Summary 
The first hypothesis tested whether there was an association between self-reported 
SDB and fundus photography identified AMD among adults 40 years and older who 
participated in the 2005–2008 NHANES survey. Diagnosed sleep apnea, self-reported 
snorting/stop breathing, snoring, and diagnosed insomnia were all identified as risk 
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factors for AMD based on OLR analyses. A multivariate model that included the 
variables sleep apnea, self-reported snorting/stop breathing, snoring, diagnosed insomnia, 
age, and BMI provided the best model fit. However, the results should be interpreted with 
caution, as the assumption of proportional odds was not met. The second and third 
hypotheses of an association between self-reported SDB and choroidal 
neovascularization or geographic atrophy, respectively had to be collapsed based on the 
small sample size of these late AMD subpopulations. Therefore, the second hypothesis 
that was tested was the association of any diagnosed sleep disorder with late AMD. There 
was no association between any diagnosed sleep disorder and late AMD based on binary 
logistic regression.  
I provide a detailed interpretation of the results in Chapter 5 and a comparison of 
these results to evidence available with regards to the association between SDB and 
AMD in the current literature. The limitations and strengths of the study will be 
evaluated. Lastly, recommendations for additional research as well as the potential 
impact that these research findings may have on social change and public health will be 
discussed.  
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Chapter 5: Discussion 
Introduction 
By the year 2050, the estimated number of people with AMD in the United States 
is expected to more than double, from 2.07 million to 5.44 million (National Eye 
Institute, 2016a). Although there has been much progress over the last decade in 
understanding the etiology of AMD, an understanding of the factors associated with the 
development and/or progression of AMD is still missing.  
In this study, quantitative data from the 2005–2008 NHANES survey were used 
to explore the association between SDB and AMD. SDB has been shown to interfere with 
current anti-VEGF treatments for neovascular AMD. Barak et al. (2012) reported that 
OSA hampered the response to anti-VEGF therapy for the treatment of neovascular 
AMD. Khurana et al. (2016) demonstrated that sleeping  more than 8 hours a day was 
associated with geographic atrophy. These results were also corroborated by research 
from Perez-Canales et al. (2016), who found a statistically significant association 
between sleep duration and AMD. In addition, Keenan et al. (2016) reported that OSA 
was positively associated with AMD. To date, there have been no published studies of 
population-based research on the association between various SDB measures and AMD.  
In Chapter 5, I interpret my findings in relation to those of previous studies and 
the life course theory. I discuss the limitations of this research and suggest future research 
that is needed to address those limitations.  Finally, I discuss the significance of this 
research in terms of its significance and potential to contribute to positive social change. 
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Interpretation of Findings 
 According to the findings of this study, SDB is associated with AMD. The 
association of a number of SDB variables with AMD remained statistically significant 
even after controlling for the sociodemographic characteristics of age, smoking status, 
and BMI. This is the first known? study on the association of numerous SDB 
characteristics with AMD in a nationally representative population of the United States. 
Study Sample and Sociodemographic Characteristics 
This study evaluated potential sociodemographic characteristics that could be 
relevant to investigating the association between SDB and AMD using a nationally 
representative sample. The NHANES sample from 2005–2008 was oversampled for 
certain race/ethnicity groups, namely Mexican Americans and Hispanics. The analysis I 
performed indicated that there is a statistically significant difference in race/ethnicity 
between the NHANES sample and the study sample. This is likely explained by the fact 
that fewer Mexican Americans had their retinal photos obtained because only 22% of the 
population was over the age of 40. To account for this oversampling, all analyses were 
performed using the weighting factors provided by NHANES.  
Preliminary chi-square analysis was performed to understand the association 
between AMD and the predefined sociodemographic characteristics (see Table 9). Age, 
race/ethnicity, smoking status, and BMI illustrated a statistically significant relationship 
with AMD. This was not unexpected because risk factors for AMD have been previously 
reported in the peer-reviewed literature: increasing age (E. Chew et al., 2014; Tomany et 
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al., 2004), non-Hispanic White race/ethnicity (T. Wong et al., 2002), past/current 
smoking status (E. Chew et al., 2014), and elevated BMI (Q. Zhang et al., 2016). There 
was a clear difference in the age categorizations of the population of participants without 
AMD as compared to those with AMD. In the group of participants without AMD, 47% 
of participants were >60 years of age, while in the group of participants with AMD 83% 
were >60 years of age. The population of non-Hispanic White in the AMD population 
was 71% compared to 53% in the population without AMD. Conversely, there were 
fewer non-Hispanic Black participants (8%) in the population with AMD as compared to 
those without AMD (21%). These racial/ethnic differences are consistent with previous 
reports from NHANES as well as other epidemiological studies, though with the addition 
to the model of the SDB variables, the observed association was negated (Klein et al., 
2011; Klein, Clegg, et al., 1999; Klein, Klein, et al., 1999; Klein et al., 2006). The 
number of current smokers in the population with AMD was 15%, while 21% of 
participants with no signs of AMD reported currently smoking. The number of current 
smokers in the 40-59-year-old category was 27%, while there were only 13% current 
smokers in the ≥ 60-year-old category. These findings are consistent with current CDC 
data showing that fewer people aged ≥65 are current smokers (Jamal et al., 2015). The 
number of participants reporting as a past smoker in the ≥ 60-year-old category was 42%, 
outweighing the 23% in the 40-59-year-old category responding as past smokers. In these 
analyses, past smokers were defined as anyone who smoked over 100 cigarettes in their 
lifetime. This definition allows for a significant amount of potential variation within the 
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group as it pertains to the overall exposure (packs of cigarettes smoked, years of 
smoking, etc.) to the harmful effects of smoking. 
There was no apparent association with gender or diabetes status in the study 
sample. Those sociodemographic characteristics that illustrated a statistically significant 
association (p < 0.1) with AMD were included in adjusted models for all SDB 
characteristics as well as multivariate models.  
As the study sample consisted of all available participants in an attempt to be able 
to study the smaller late AMD population, it was important to investigate whether the 
study sample was representative of the NHANES sample. A chi-square Goodness of Fit 
was performed to assess whether the study sample was similar to the overall NHANES 
sample as it pertained to these characteristics. Only gender and smoking status were 
found to reflect the NHANES sample. The other characteristics were statistically 
significant illustrating a dissimilar distribution in both populations. As age and BMI are 
included in the multivariate analysis and weighting is based on the original sample, I 
must use caution when interpreting the association of these variables to AMD.  
Association of SDB with AMD 
Preliminary chi-square analysis was performed to investigate the association of a 
number of SDB characteristics with AMD (Table 10). There was a statistically significant 
association with AMD in participants that self-reported a doctors’ diagnosis of any sleep 
disorder or sleep apnea. In addition, there was a statistically significant association with 
AMD in those participants reporting snorting, gasping, or cessation of breathing. There 
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were no associations between AMD and snoring, insomnia, prolonged sleep latency, 
nocturnal awakenings, hypersomnolence or sleep duration. Regardless of association, 
SDB variables were included in both adjusted and unadjusted OLR models.  
Any sleep disorder. SDB variables were analyzed using Complex Samples OLR 
models (Table 10). Those participants with any self-reported diagnosed sleep disorder 
(sleep apnea, insomnia, restless leg syndrome, or other) were two times (OR, 2.2; 95% 
CI, 1.2-3.9) more likely to have AMD than those without a diagnosed sleep disorder. This 
is the first report of an association with an open-ended query for any diagnosed sleep 
disorders from a population based sample. The association remained statistically 
significant even after adjustment for covariates (age, smoking status, and BMI). As the 
understanding and identification of sleep disorders has evolved and improved over the 
last decade, it is possible that the number of participants with diagnosed sleep disorders is 
low during the 2005–2008 survey periods as compared to more recent sampling frames. 
The HypnoLaus study that collected data from 2009-2013 reported SDB prevalence to be 
as high as 49% and 23% of men and women in Switzerland, respectively (Heinzer et al., 
2015). It has been postulated that this higher prevalence is due to the improved sensitivity 
of SDB recording techniques and to a newer definition of respiratory events (particularly 
the hypopnea definition) (Heinzer, 2016). 
Sleep apnea. Sleep apnea has been previously reported to be associated with 
AMD in a large national health service cohort in the United Kingdom (Keenan et al., 
2016). The current study based on the U.S. population corroborates these findings with 
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those with a diagnosis of sleep apnea 2.6 times (OR, 2.6; 95% CI, 1.4-5.1) more likely to 
develop AMD as compared to those participants without diagnosed sleep apnea. The 
odds of having AMD in participants with sleep apnea remained unchanged even after 
adjustment for sociodemographic variables. Fraser et al. (2013) performed a prospective 
fundus photographic study of patients undergoing PSG in a community sleep center. 
Retinal vascular changes were much more common in patients with sleep apnea, even 
after controlling for history of diagnosed hypertension (Fraser et al., 2013). AHI>40 
conferred a doubling of the odds of retinal vascular changes as compared to those with 
AHI<5, even after controlling for confounding variables. Research by Nesmith et al. 
(2014) provided some insight into an underlying mechanism whereby sleep apnea is 
shown to exert pathological changes on the underlying retinal vasculature. In their study, 
the researchers investigated patients that were refractory (defined as persistent subretinal 
fluid after 3 consecutive injections) to treatment with anti-VEGF medications, the current 
standard of care for neovascular AMD. VEGF blocking agents have been shown to exert 
their effects on the retina by reducing vascular permeability and improving retinal edema 
and subretinal fluid (CATT Research Group, 2011). The result that more patients with 
OSA in this study were found to have refractory subretinal fluid indicated that sleep 
apnea modifies retinal vascular permeability despite anti-VEGF therapy. This same 
phenomenon was noted by Barak et al. (2012) who also noted that the fluid accumulation 
could be reversed once CPAP therapy for sleep apnea was initiated.  
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One potential theory to explain the underlying etiology of this phenomenon is the 
presence of circulating inflammatory proteins. Zychowski et al. (2016) incubated human 
endothelial cells with serum from patients with sleep apnea and healthy controls. In 
patients with sleep apnea, the cell cultures resulted in greater serum inflammatory 
potential, thereby driving endothelial activation/dysfunction (Zychowski et al., 2016). 
Importantly, collecting serum from the same sleep apnea patients after initiation of CPAP 
therapy resulted in a reduction in endothelial cell inflammatory potential and 
activation/dysfunction. Sleep apnea is a chronic disease that goes undiagnosed in much of 
the affected population, sometimes for decades. Chronically exposing the vulnerable 
retina vasculature to recurrent hypoxia, resulting in persistent circulating inflammatory 
proteins, may explain the underlying cause for the association evident in this study.  
Insomnia and Sleep Duration. This study is the first to look directly at the 
association of diagnosed insomnia with AMD. In the study sample, those with diagnosed 
insomnia were three times (OR, 3.1; 95% CI, 1.1-9.0) as likely to have AMD as those 
without a diagnosis of insomnia. When adjusted for sociodemographic characteristics, 
diagnosed insomnia no longer had a statistically significant association with AMD. 
Interestingly, insomnia has been associated with neurodegenerative disorders such as 
Alzheimer’s and Parkinson’s disease and the deposition of Aβ (Keene & Joiner, 2015). 
With Aβ deposition noted as a drusen component, I must consider the possibility that 
similar mechanisms could be at play with AMD pathogenesis promoted by SDB. 
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 In this study, sleep duration did not demonstrate a statistically significant 
association with AMD. In the literature, AMD was shown to be associated with sleep 
duration, although the reports in the literature have been specific to geographic atrophy 
and choroidal neovascularization, and not early AMD (Khurana et al., 2016; Perez-
Canales et al., 2016). The findings from the current study may be consistent with the 
literature reported associations with late AMD, although the OLR modelling was not 
designed to answer this question. In addition, there were a very small number of 
participants with late AMD in the study sample. I will discuss this lack of participants in 
the study sample with fundus photograph identified late AMD in more detail as it pertains 
to RQ 2. 
Snorting/Gasping/Stop Breathing and Snoring. Snorting/Gasping/Stopping 
breathing during sleep is representative of a decrease in oxygen saturation that stimulates 
arousal and can be quantified using AHI scores. AHI values have been associated with a 
reduction in RNFL thickness (Huseyinoglu et al., 2014; Shiba et al., 2014). 
Snorting/Gasping/Stopping Breathing in this study was statistically significant for an 
association with AMD, illustrating a three (OR, 2.8; 95% CI, 1.3-6.0) times greater odds 
of having AMD. This continued to be statistically significant even after adjusting for 
covariates. Snoring was also significantly associated with AMD, introducing a 1.5 times 
(OR, 1.5; 95% CI, 1.1-2.0) greater likelihood of AMD. Snoring did not remain 
statistically significant after adjusting for covariates.  
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Prolonged Sleep Latency, Nocturnal Awakenings and Hypersomnolence. 
Prolonged sleep latency, nocturnal awakenings, and hypersomnolence, were not 
associated with AMD. The responses to these survey questions may be subject to 
significant recall bias as the answers may not be as easy to remember as compared to 
answering whether there was a previous doctor’s diagnosis of sleep disorders such as 
sleep apnea or insomnia. Therefore, it is hard to interpret whether the lack of association 
is accurate, or if the instrument was not sensitive enough to detect the association.  
Sociodemographic Characteristics 
Age. As expected, increased age was highly statistically associated with AMD in 
all models. In the current study, using multivariate OLR modelling, age ≥60 conferred 
more than five times the likelihood of developing AMD as compared to those in the 45-
59-year-old category. The increased odds associated with increasing age were consistent 
and statistically significant across all adjusted models and in multivariate modelling. 
Even with the advent of anti-VEGF therapy, AMD is a leading cause of permanent 
blindness in adults aged 60 and older in the United States, and present in more than 14% 
of White Americans over the age of 80 (NEI, 2016a).  
Smoking. Smoking has been consistently shown in the literature to be the most 
strongly associated modifiable risk factor for AMD (E. Chew et al., 2014; Evans, 
Fletcher, & Wormald, 2005). In this study, smoking was strongly associated AMD when 
assessed using the chi-square test of association (p < .001). When smoking was 
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incorporated into multivariate models, the OR was 1.1 indicating a non-statistically 
significant contribution to the prediction of AMD. 
BMI. BMI has previously been shown to be mildly associated with AMD (Q. 
Zhang et al., 2016) and significantly associated with SDB (Heinzer et al., 2015). In this 
study, BMI was associated with AMD when assessed using the chi-square test of 
association (p < .02). When BMI was incorporated into the multivariate models this 
statistically significant association with AMD was negated. 
Multivariate Modelling. Multivariate modelling was performed on independent 
variables and covariates that demonstrated a statistically significant association (P<0.1) 
with chi-square tests of association and/or OLR. A model was built that included 
diagnosed sleep apnea, diagnosed insomnia, snoring, snorting/gasping/stop breathing, and 
snoring as independent variables. Age, smoking status, and BMI were included as 
covariates. The multivariate model provided the best model fit compared to all other 
univariate models. 
Association of SDB with Late AMD   
Keenan et al. (2016) demonstrated an association between AMD and sleep apnea 
in a record linkage study from the United Kingdom. Based on this data, and the findings 
from Fraser et al. (2013) that illustrated increased prevalence of vascular changes with 
sleep apnea, I hypothesized that sleep apnea may be associated with choroidal 
neovascularization. Additionally, Khurana et al. (2016) have shown an association with 
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sleep duration and geographic atrophy, so it is plausible that a diagnosed sleep disorder 
may have an association with atrophic changes in the retina. 
The prevalence of AMD in the study sample was 6.9%, consistent with estimates 
from the same survey periods previously reported by Klein et al (2011). Late AMD was 
present in only 1.0% of the sample; therefore, adjustments were made to the original 
analysis plan which divided choroidal neovascularization and geographic atrophy into 
separate research questions. As the presence of late AMD disease was so rare in the study 
sample, I collapsed the choroidal neovascularization and geographic atrophy categories to 
form a single late AMD variable for analyses. Similarly, the omnibus variable for any 
diagnosed sleep disorder (NHANES questionnaire choices included sleep apnea, 
insomnia, restless leg syndrome, and other) was used in the analysis to assure model 
saturation. The model included the covariates of age, smoking status, and BMI as used in 
the OLR analyses. There was no association found with any diagnosed sleep disorder and 
AMD. Based on a post-hoc power calculation, it would take approximately 1039 
participants to detect a moderate OR of 1.5. Therefore, it is likely that the available 
number of participants in the study sample with late AMD (n=55) was not robust enough 
to provide the power to detect an association.  
Overall Findings 
In using the life course theory of chronic disease as the framework for this 
quantitative cross-sectional study, I was able to find significant associations between a 
number of SDB variables and AMD. Although the OLR analyses did not meet the 
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assumption of proportional odds due to the small number of participants with late AMD, 
the ORs from the OLR were almost identical when performing separate binomial logistic 
regression for any AMD. These findings provide confidence that the interpretation of 
association is valid and that it is primarily driven by the participants with early AMD in 
this sample. The application of the life course theory of chronic disease in this study 
posited that SDB would have a temporal relationship with presentation of early AMD in 
exposed participants. As previously stated, there is a temporal relationship between the 
age of peak presentation of SDB and the age at which signs associated with early AMD 
are evident (Bixler et al., 1998; Bourne et al., 2014). The findings of the current study 
implicated SDB as a factor along the life course of the AMD patient and represent 
another modifiable risk factor that could be addressed with public health intervention.  
There are several strengths of the current study. First, the dependent variable for 
AMD was assessed using independent grading of retinal photographs. This allowed for a 
highly objective measure to assess AMD classification and eliminated participant recall 
biases that would be present if this data was collected from a questionnaire. Second, the 
study participants are a nationally representative sample of the U.S. civilian non-
institutionalized population from the NHANES 2005–2008 survey. The sample has a 
nearly equal distribution of men and women and has been over-sampled to allow for an 
assessment of association in under-represented racial/ethnic groups. The multi-stage 
sampling scheme employed by NHANEs may reduce the referral biases that have been 
noted in studies using sleep-clinic based populations (Seicean et al., 2011). Lastly, a 
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robust set of statistical analyses was performed by applying chi-square, OLR, and 
multivariate logistic regression analyses to examine the associations between AMD and 
SDB. 
Limitations of the Study 
There are several limitations to this study. The NHANES survey is a cross-
sectional survey by design, and therefore the data was collected at one single point in 
time. Due to this limitation, longitudinal trends in health behavior cannot be examined. 
This study is correlational in nature, and as such, care must be taken when interpreting 
the results. Although statistically significant associations were identified between AMD, 
SDB-related variables, and other covariates; causality cannot be assessed. 
Although one of the strengths of this study is that the AMD variable was assessed 
by independent photography graders using a standardized protocol and definitions for 
findings, the SDB variables were all questionnaire derived. Recall bias may have led to 
misclassification of participants that could have impacted my results. The gold standards 
for defining SDB are an airway evaluation with an accompanying polysomnographic 
(overnight sleep study) assessment. This would have been a more objective measure of 
SDB as compared to questionnaire data, although this is not part of the examinations 
offered for NHANES, likely due to its inherently high cost.  
The NHANES survey is a useful tool to assess the health of the U.S. population. 
One of the limitations of the survey is that data collection is limited to civilian, non-
institutionalized U.S. citizens (CDC, 2011). Therefore, the results of this study cannot be 
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generalized to the non-civilian or institutionalized populations of the United States or 
abroad. With AMD primarily affecting the elderly, the institutionalized population may 
be an important population to consider in future attempts to understand the true 
magnitude of the association between SDB and AMD.  
There were a number of limitations based on the composition of the study sample. 
First and foremost, the small number of participants with late AMD required a 
modification of the   analysis plan. Additionally, not all participants participated in the 
MEC acquisition of fundus photos. Although the sample that had fundus photography 
performed was similar in sociodemographic characteristics to the sample that did not 
have photos taken, the exclusion of those without this exam reduced the available sample 
size and therefore my power to detect significant differences. Some of the reasons for not 
having photos taken included participants having no light perception, severe visual 
impairment in both eyes, or an infection in at least one eye (CDC, 2005). Those 
participants with no light perception or severe visual impairment in both eyes may have 
actually had AMD, and likely late AMD, and therefore may have reduced the available 
number of cases with disease in the data set.  
In the 2005–2008 sampling timeframes, there were a number of ethnic and age 
groups oversampled in NHANES (National Center for Health Statistics [U.S.], 2013). 
Although this may have allowed for better estimation of association in these groups, it is 
possible that this oversampling could have had unseen adverse consequences with regard 
to the results of the non-Hispanic White group that has the highest prevalence of AMD in 
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the U.S. population. The NHANES survey may not contain a representative sample of 
some ethnic groups as the data collected included Non-Hispanic Whites, Non-Hispanic 
Blacks, Mexican-Americans, other Hispanic, and all other groups are lumped into the 
“Other Race” category (Johnson et al., 2013). Therefore, certain ethnic groups such as 
Asian-Americans are not represented in the dataset and the association with SDB and 
AMD is unable to be assessed. While weighting is available to adjust for the sampling 
scheme, it is based on the full and not the reduced sample I was able to use for this 
sample. 
 Lastly, the assumption of proportional odds was not met when performing OLR 
analyses. Separate binomial logistic regressions were performed using cumulative 
dichotomous dependent variables to test this assumption. It was clear that the number of 
participants in the “Late AMD” category was too small to support the assumption of 
proportional odds and therefore the ordinal nature of the dependent variable was lost. By 
collapsing the AMD category into “Any AMD” the ORs for the association of SDB 
variables and AMD were able to be calculated meeting all assumptions of this analysis. 
In interpreting the results of this study, I recognized that the resultant ORs were driven 
primarily by participants with early AMD and not late AMD. 
Recommendations 
Although the study indicated that there is a statistically significant association 
between SDB and AMD, I was unable to investigate causality. Future research should be 
performed to define the causal link between SDB and AMD. The collection of 
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longitudinal data starting with an early diagnosis of SDB by polysomnography in 
individuals under the age of 50 followed by regularly scheduled retinal examination 
and/or diagnostic imaging would further enhance the body of research available on SDB 
and AMD.  
The understanding of this association would be further enhanced by diagnosis of 
SDB by more objective sleep quality measures such as polysomnography instead of 
participants responding to a questionnaire. Young et al. (1997) have shown that as many 
as 82% of men and 92% of women with SDB are undiagnosed and therefore a study with 
a large cohort screened by polysomnography could provide more accurate classification 
of SDB as compared to the current study. When coupled with independently graded 
retinal photography, this screening could provide a powerful, albeit costly, dataset for 
answering this important research question. 
I was unable to investigate the association between SDB and choroidal 
neovascularization or geographic atrophy. Future research should be directed at 
understanding the association in those participants who develop late AMD. Among the 
group of subjects that present with choroidal neovascularization with SDB the data 
suggests a higher incidence of retinal vascular abnormalities; this warrants further 
evaluation in an enriched population. 
This study used data from the most recent NHANES survey periods where retinal 
photography was incorporated. In contrast, the sleep questionnaire has been administered 
a number of times from 2005-2014. Future research could include retinal photography as 
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a part of examination data in conjunction with the sleep questionnaire to allow this study 
to be replicated. In addition, current NHANES questionnaires include non-Hispanic 
Asian as an ethnic/race category, therefore the association between SDB and AMD could 
be investigated in the Asian population. 
Implications 
The findings from this study have the potential to have a profound and positive 
impact on social change. AMD prevalence is expected to double in the next three decades 
(NEI, 2016b). It is estimated that the global cost of visual impairment due to AMD is 
$343 billion, including $255 billion in direct health care costs (BrightFocus Foundation, 
2016). The ability to prevent AMD represents a significant opportunity for saving 
healthcare costs in the United States and other industrialized countries. Currently, there 
are no therapies proven to prevent AMD, only to treat AMD symptoms once diagnosed. 
Potential modifiable risk factors that have shown some promise in reducing AMD 
incidence include diet and smoking. SDB represents a third modifiable risk factor that if 
diagnosed and treated could have an impact on new cases of AMD. Public health 
programs that develop SDB screening guidelines and subsequently promote treatment 
compliance could have a major impact on AMD and a number of other potential 
complications of SDB.  
At the individual patient level, SDB diagnosis rates as well as CPAP treatment 
compliance are notoriously poor. Public health practitioners may choose to use the fear of 
blindness as a motivating factor to get patients to get screened for SDB as well as to 
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promote continued adherence to CPAP therapy. Improving screening of SDB patients and 
adherence to SDB therapy of specific individuals and at-risk populations will aid the 
public health community in meeting the objectives for Healthy People 2020, specifically 
to reduce vision impairment due to AMD (Office of Disease Prevention and Health 
Promotion, 2016).  
Currently, sleep medicine practitioners and retina specialists do not co-manage 
patients. The current guideline for OSA states that disease management should be as a 
chronic condition, using a multidisciplinary approach (Epstein et al., 2009). However, 
there is no mention of ophthalmology and/or eye health in the OSA guidance. This study, 
in addition to those aforementioned in the literature review, creates a growing body of 
evidence that SDB is associated with AMD and can have a negative impact on treatment 
outcomes for patients with AMD. The current Preferred Practice Patterns for AMD 
published by the American Academy of Ophthalmology (AAO) mentions a number of 
risk factors for AMD although SDB was not listed as one of them (AAO, 2015). 
Increasing healthcare practitioners’ understanding of the association of SDB and AMD 
may encourage their incorporation of screening and preventative measures into delivery 
of care guidelines. 
Conclusions 
Based on my extensive literature review, I believe this was the first research study 
to investigate the association between SDB and AMD in a civilian, non-institutionalized 
population of the United States. The results from this cross-sectional study suggest that 
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AMD is associated with diagnosed sleep disorders including sleep apnea and insomnia, 
as well as sleep apnea symptoms (snorting/gasping/stop breathing and snoring). 
Furthermore, these associations were independent of sociodemographic and lifestyle 
factors. AMD can be added to the growing list of chronic diseases that have been linked 
to SDB such as cardiovascular disease and Alzheimer’s disease. 
Future research should aim to look at the association of SDB with late AMD 
(choroidal neovascularization and geographic atrophy). Study designs should employ the 
most objective measures available for assessing SDB (polysomnography) and AMD 
(multimodal retinal diagnostic imaging). Additionally, research is needed to determine 
causal relationships that will help direct interventional and preventative public health 
programs.
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